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Abstract  
 
The classical concept of neuropeptides considers them as peptides that act on nervous 
tissue and either are co-expressed with classical transmitters or act as hormones. It later 
became clear, however, that neuropeptides are in fact found throughout the body and have 
effects also on peripheral tissues. Neuropeptides typically have numerous functions and may 
have hormone-like effects. They are classified by structure, function or site of expression.  
The precursor molecules are large and often multiple copies of the same peptide, or several 
distinct, biochemically active peptides may be spliced from the same precursor. 
Neuropeptides act through and bind to multiple types of receptors mediating diverse 
functions.  
 The RFamide (R=arginine, F=phenylalanine) peptides are a group of neuropeptides 
that share the C-terminal RF-NH2 –structure. Neuropeptide FF was the first one 
characterized among these peptides, and our aim was to clone the gene for the peptide 
precursor and show the mRNA distribution in normal and stimulated situations. During the 
preparation of this work, other researchers found several other RFamides. The prolactin-
releasing peptide was the second RFamide and was chosen to be studied in parallel with 
neuropeptide FF to reveal possible similarities and differences between the two peptides.  
Both peptides occur in the medulla and hypothalamus though in distinct nuclei: e.g., 
PrRP in the caudal, and NPFF in the rostral division of the nucleus of the solitary tract. Only 
neuropeptide FF occurs in the spinal cord. According to our findings, the appearance of the 
peptide mRNAs during embryonal development is distinct and suggests that from early 
developmental stages, the roles of these peptides differ. Both peptides occur in a limited 
number of peripheral tissues (NPFF only in the spleen, PrRP in male reproductive organs, 
kidney, and liver) and are involved in nociceptive modulation: the prolactin-releasing peptide 
through a medullary mechanism (analgesic through nucleus of the solitary tract and 
hyperalgesic through caudal ventrolateral medulla) and the neuropeptide FF through both 
medullary (antiallodynic) and spinal (analgesic) mechanisms. Neuropeptide FF, but not 
prolactin-releasing peptide mRNA, is regulated by chronic hyperosmotic stimulus.  
 In conclusion, these two neuropeptides, although occurring in the central nervous 
system in adjacent areas, obviously have distinct functions. In addition, these results suggest 
a possible new mechanism for the transcriptional regulation of neuropeptide FF. 
 7
List of original publications: 
 
The experiments and conclusions in this thesis are based on the following original 
communications, referred to in the text as Roman numerals I to IV. In addition, some 
unpublished results are presented.  
  
 
I Vilim F.S., Aarnisalo A.A., Nieminen M.-L., Lintunen M., Karlstedt K., Kontinen V.K., Kalso 
E., States B., Panula P. and Ziff E. Gene for pain modulatory neuropeptide FF: 
induction in spinal cord by noxious stimuli. Mol. Pharmacol. 1999; 55(5): 804-811. 
 
II Kalliomäki M.-L. and Panula P. Neuropeptide FF, but not prolactin-releasing peptide, 
mRNA is differentially regulated in the hypothalamic and medullary neurons after salt 
loading. Submitted. 
 
III Nieminen M.-L., Nystedt J. and Panula P. Expression of neuropeptide FF, prolactin-
releasing peptide and the receptor UHR1/GPR10 genes during embryogenesis in the 
rat. Dev. Dyn. 2003; 226: 561-569. 
 
IV Nieminen M.-L., Brandt A., Pietilä P., Panula P. Expression of mammalian RFamide 
peptides neuropeptide FF (NPFF), prolactin-releasing peptide (PrRP) and the PrRP 
receptor in the peripheral tissues of the rat. Peptides 2000; 21:1695-1701. 
 
 
 
 
 
 
 
 8
List of abbreviations 
 
ACTH  adrenocorticotropin 
bp  base pairs (of the gene sequence) 
cAMP  cyclic adenosine mono phosphate 
cDNA  complementary deoxyribonucleic acid 
cGMP  cyclic guanylyl mono phosphate 
E1  embryonal day 1 
FMRFamide molluscan neuropeptide with phenylalanine-methionine-arginine-  
                          phenylalanine amino acid sequence at the carboxyterminus 
HPLC  high-pressure liquid chromatography 
i.v.   intravenous 
mRNA  messenger ribonucleic acid 
MSH  melanocyte-stimulating hormone 
NPAF  neuropeptide AF, AGEGLSSFWSLAAPQRF-NH2 
NPFF  neuropeptide FF, FLFQPQRF-NH2 
NPSF  neuropeptide SF, SLAAPQRF-NH2 
NPY  neuropeptide Y 
OXY   oxytocin 
P0  postnatal day 0 
PIP   phosphatidyl inositol 4,5-bisphosphate 
POMC  pro-opiomelanocortin  
PPTA  preprotachykinin B 
PPTB  preprotachykinin A 
PrRP  prolactin-releasing peptide  
RER  rough endoplasmic reticulum  
RFamide mammalian neuropeptide corresponding to molluscan FMRFamide 
RT-PCR reverse transcriptase polymerase chain reaction 
SP  substance P  
VIP  vasoactive intestinal peptide 
VP  vasopressin 
 
Amino acids and their symbols: 
A  alanine 
C  cysteine 
D  aspartic acid 
E  glutamic acid 
F  phenylalanine 
G  glycine 
H  histidine 
I  isoleucine 
K  lysine 
L  leucine 
M  methionine 
N  asparagine 
P  proline 
Q  glutamine 
R  arginine 
S  serine 
T  threonine 
V  valine 
W  tryptophan 
Y  tyrosine 
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1. Review of the literature 
 
1.1 General aspects of neuropeptides 
Neuropeptides (De Wied et al. 1969, Kastin et al. 1979) are small proteins in neurons mostly 
co-expressed with classical transmitters or hormones (Hökfelt 1991, Lundberg 1996). They 
are expressed throughout the nervous system and are also present in a variety of peripheral 
tissues. Once they were thought to act on neural tissues only, but nowadays their role is 
understood as an integrating tool between the peripheral organs and nervous tissue. 
Neuropeptides act as neurohormones, as neurotransmitters, and as neuromodulators. The 
hormones are regarded as agents mediating their effects at long distances through the 
circulation, and the transmitters as affecting only locally the nearby (paracrine) or the same 
(autocrine) cells. These neurotransmitters must, by definition, be synthesized in the 
presynaptic terminals and be released by them upon nerve stimulation. A neuromodulator is 
traditionally understood as an agent that does not evoke an effect on its own, but alters the 
responses induced by a classical transmitter pre- or postsynaptically. Some of the main 
properties of neurotransmitters and neuromodulators are considered in Table 1, in which 
corresponding properties of neuropeptides are compared, as well. 
 
Table 1. Properties of neurotransmitters, neuromodulators, and neuropeptides. (Modified from Strand: 
Neuropeptides: regulators of physiological processes, 1999, MIT Press and (Hökfelt et al. 2000). 
EPSP=excitatory postsynaptic potential, IPSP=inhibitory postsynaptic potential, RER=rough 
endoplasmic reticulum. 
 
FUNCTION NEUROTRANSMITTER NEUROMODULATOR NEUROPEPTIDE 
Release Induced by high Ca2+ 
influx 
Dependent on action 
potential, 
intermittent/continuous 
Caused by small 
fluctuations in Ca2+ 
Reuptake 
mechanisms 
Active  No  No, but degraded in the 
intercellular space  
Localization Near the synapses Not restricted to the 
synapse  
Not restricted to the 
synapse  
Synthesis In the soma, but also in 
the nerve endings 
- Only ribosomal de novo 
synthesis, axonal 
transportation to the 
nerve endings 
Transportation Directly to the mature 
secretory granules 
- Through the RER to 
secretory granules 
Coexistence Can be found alone in the 
vesicles 
With transmitters With transmitters or alone 
Structure Constant  May vary and as 
consequence of  
biological activity 
- 
Potency Low High High  
Effect on 
postsynaptic 
membrane 
Excitatory (EPSP) and 
inhibitory potential (IPSP) 
Affects postsynaptic 
membrane, but 
incapable of evoking 
EPSP or IPSP: 
modulates transmitters 
Affects postsynaptic 
membrane, but incapable 
of evoking EPSP or IPSP: 
modulates transmitters 
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One should keep in mind, however, that the definition of an agent should be considered site-
specifically, e.g., substance P fulfills the criteria of a neurotransmitter in the spinal cord, but 
modifies the action of acetylcholine on its receptor in the spinal ganglia.  
Most commonly, neuropeptides are designated according to a structure in their 
sequence (e.g., neuropeptide Y) or to their first-discovered function (e.g., gastrin-releasing 
peptide), even though they are usually later shown to be involved in various functions. First, 
the neuropeptides were divided into groups according to site of origin, but this became 
difficult, since the peptides are found in many organs. An attempt to classify some important 
neuropeptides in the families appears in Table 2. 
The peptide precursor molecules are usually large, containing one or more copies of 
the same peptide and/or a related peptide with possibly other expression patterns and 
functions. For example, the pro-opiomelanocortin (POMC) contains several bioactive peptide 
sequences: α-, β-, and γ-melanocyte-stimulating hormone (MSH) and in additon β-
lipoprotein, adrenocorticotropin (ACTH), and β-endorphin. The existence of several copies of 
the same peptide in the precursors provides evidence of gene duplication. During evolution, 
minor changes or attributions in gene duplication have occurred, resulting in slightly different 
sequences of the same peptide in different species. Acher (1980) described the evolution of 
vasopressin and oxytocin: They evolved from the same ancestral precursor. The first gene 
duplication resulted in the generation of two distinct peptides with different activities: 
vasopressin and oxytocin. The next duplications caused minor sequence differences 
between teleosts, amphibians, reptiles, and mammals. Even though the peptide is highly 
homologous, the receptors usually prove to have less homology: The vasopressin is identical 
in the rat and human being, but the receptors have only 50% homology (Hoyle 1999).  
Large, hydrophobic, and high molecular-weight molecules such as peptides have 
difficulty in penetrating the blood-brain barrier. Some peptides may, however, cross the 
blood-brain barrier by transmembrane diffusion (Banks and Kastin 1985) related to peptide 
hydrogen bonding (Chikhale et al. 1994), as does vasopressin, or by saturable bi- (Barrera et 
al. 1991) or unidirectional (Barrera et al. 1987) transport systems. Peptides are also capable 
of altering the blood-brain barrier permeability to other substances: Melanocortins can alter 
the tight junctions or passive membrane diffusion and thus facilitate the passage of some i.v.-
introduced radiolabeled agents that are generally considered markers of blood-brain barrier 
integrity (Rudman and Kutner 1978). 
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Table 2. Examples of neuropeptide families. See list of abbreviations for amino acid symbols. 
 
FAMILY PEPTIDES AND ABBREVIATIONS STRUCTURAL SIMILARITY 
Bombesin-like 
peptides 
Bombesin 
Gastrin-releasing peptide                 GRP 
Neuromedin B                                   NMB 
Rantesin 
C-terminal WAVGHXM 
Endogenous opiates Proenkephalin 
Prodynorphin 
Pro-opiomelanocortin                      POMC  
3 genes: overall similarity, similar size 
and position of introns, 6 cysteines near 
N-terminus 
Calcitonin gene-
related peptides 
Calcitonin                                         CT 
Calcitonin gene-related peptide       CGRP 
CGRP developed by alternative splicing 
from CT 
Cholecystokinin Cholecystokinin                                CCK 
Gastrin 
C-terminal GWDMF 
Hypothalamic 
peptides  
Oxytocin                                           OXY 
Vasopressin                                      VP 
CYXQNCPXG-NH2  
Hypothalamic 
releasing peptides 
Corticotropin-releasing hormone             
CRH 
Growth hormone-releasing hormone       
GHRH                                                 
Luteinizing hormone-releasing hormone  
LHRH 
Thyrotropin-releasing hormone                
TRH 
- 
Insulin-like growth 
factors  
Insulin 
Insulin-like growth factors 
Relaxin 
Similar primary and tertiary structures 
Neurotensin Neuromedin 
Neurotensin                                        NT 
C-terminal PYIL 
Pancreatic 
polypeptides  
Neuropeptide Y                                  NPY    
Pancreatic polypeptide                       PP     
Peptide YY                                         PYY 
Similar structure of the precursor. 24% 
homologous active peptides 
RFamide peptides  KiSS-peptides                                  KiSS   
Neuropeptide FF                              NPFF    
Neuropeptide SF                              NPSF 
Prolactin-releasing peptide              PrRP 
P518 
RFRPs                                             RFRP 
C-terminal RF-NH2 
Somatostatin Somatostatin                                    SS - 
Somatotropins  Choriomammotropin                         PL   
Growth hormone                              GH 
Prolactin                                           PRL     
Ancestral prototype-GH-PRL. >90% 
similarity of coding regions 
Tachykinins Neurokinin A                                    NKA   
Neurokinin B                                    NKB 
Substance P                                    SP 
Bradykinin 
C-terminal FXGLM 
VIP-secretin-
glugacon-family 
Gastric inhibitory peptide               GIP 
Glucagon 
Pituitary adenylate cyclase-activating 
peptide                                           PACAP 
Secretin 
Vasoactive intestinal peptide 
Similar structural organization of the 
genes 
 
1.2 The RFamide family of neuropeptides 
Currently five genes are known to encode several RFamide peptides in mammals (Perry et 
al. 1997, Hinuma et al. 1998, Hinuma et al. 2000, Kotani et al. 2001a, Liu et al. 2001, Jiang 
et al. 2003). In invertebrates, over 20 peptides have been characterized. FMRFamide 
peptides are encoded in genes that contain multiple copies of active peptides in 
invertebrates. The mammalian FMRF-crossreactive peptides are larger, and their precursor 
contains only one copy of the peptide, each of which contains C-terminal glycines. The first 
RFamide peptide recognized was FMRFamide, a cardioexcitatory peptide in mollusks (Price 
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and Greenberg 1977), also involved in modulation of opiate-induced
 
analgesia (Tang et al. 
1984). Yang et al. (1985a) isolated from bovine brain in 1985 by HPLC-purification two 
FMRF-NH2 crossreacting peptides, FLFQPQRF-NH2 and AGEGLSSPFWSLAAPQRF-NH2. 
These two neuropeptides are derived from the same precursor. The second RFamide 
peptide, the prolactin-releasing peptide, was found in 1998 as a ligand for an orphan G 
protein-coupled receptor UHR1/GPR10-like receptor (Hinuma et al. 1998). Majane and Yang 
(1987) ―since their HPLC experiments revealed in the brain other immunoreactive materials 
in addition to FLFQPQRF-NH2 and AGEGLSSPFWSLAAPQRF-NH2 ―found evidence of 
several related neuropeptides. Immunohistochemical data (Panula et al. 1996) also showed 
specific FLFQPQRF-NH2 -immunofluorescent staining in a cell group between the 
dorsomedial and ventromedial hypothalamus, which in later studies appeared to express 
another neuropeptide (Maruyama et al. 1999, Minami et al. 1999).  
Indeed, soon another RFamide peptide was characterized as a ligand for an orphan 
receptor expressed in the hypothalamus (Hinuma et al. 1998). This peptide was capable of 
releasing prolactin, and was designated prolactin-releasing peptide, PrRP. The preproprotein 
of PrRP also contains two possible sequences for mature peptides, 
SRAHQHXMEIRTPDINPAXYAGRGIRPVG and TPDINPAWYAGRGIRPVGR, called PrRP31 
and PrRP20, respectively. The PrRP20 may be a cleaved form of PrRP31. Three TATA 
boxes exist in the gene, the one located at –92bp being crucial for gene expression. The 
PrRP gene contains three exons and two introns, the second intron being located precisely 
at the cleavage site of PrRP20 from PrRP31. Exon 1 encodes the 5´region; exon 2 starts the 
sequence of PrRP31; the last exon encodes for the rest of the coding sequence, comprising 
PrRP20 and the 3´untranslated region. (Yamada et al. 2001). The structural organization of 
the gene is shown in Figure 5 on page 37.  
Two groups searched the human genome databases independently and succeeded 
in isolating an unknown peptide precursor encoding for two mammalian peptides: RFRP-1 
(MPHSFANLPLRF-NH2) and RFRP-3 (VPNLPQRF) or NPSF and NPVF (Hinuma et al. 
2000, Fukusumi et al. 2001). High homology appeared between human, rat, mouse, bovine, 
and quail genes (Hinuma et al. 2000, Liu et al. 2001). The C-terminal amino acids of hRFRP-
3 are identical to those of NPFF, and the four C-terminal amino acids of hRFRP-1 coincide 
with the chicken LPLRF-NH2 (Dockray et al. 1983), suggesting for the peptides a common 
evolutionary ancestor. The in situ hybridization studies of these peptides revealed peptide 
mRNA and immunoreactivity in the hypothalamus near the third ventricle between the 
dorsomedial and ventromedial nuclei (Hinuma et al. 2000, Fukusumi et al. 2001), exactly 
where NPFF immunoreactivity had been evident.  
The third new peptide precursor, KiSS-1 (Lee et al. 1996, Lee and Welch 1997) 
encodes for four kisspeptins: -10, -13, -14, and –54, numbers indicating the number of amino 
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acid residues in the corresponding peptide. The sequence of kisspeptin–54 (also called 
metastin) is flanked by basic residues, which indicates that the peptide is cleaved from the 
precursor by furin or prohormone convertases. The shorter fragments are most likely 
degradation products of the kisspeptin-54 
(GTSLSPPPESSGSRQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGLRF-NH2).  
The kisspeptins were isolated from human placenta and were shown to be capable of 
releasing oxytocin (Kotani et al. 2001a). KiSS-1 gene expression has been detected most 
abundantly in the placenta, but also in the testis, pancreas, liver (Ohtaki et al. 2001), and 
brain (Muir et al. 2001).  
Recently, Jiang et al. (2003), using a novel computational approach, succeeded in 
finding a novel ligand for an orphan G protein-coupled receptor SP9155. This ligand, called 
P518, shares the RF terminus with these peptides and is expressed in the brain, coronary 
arteries, thyroid and parathyroid glands, testes, prostate, large intestine, and colon of the 
human and the mouse. The precursor of this peptide also contains multiple putative bioactive 
peptides.  
All currently known RFamide peptides are listed in Figure 1.  
NPAF       AGEGLSSPFWSLAAPQRF-NH2  bovine            1 
NPAF human          AGEGLNSPFWSLAAPQRF-NH2  human             1 
NPSF                        SLAAPQRF-NH2  bovine, human     1 
NPFF                        FLFQPQRF-NH2  bovine, human     1 
GnIH-RP-2                 SSIQSLLNLPQRF-NH2  quail             2 
FGRP                   SLKPAANLPLRF-NH2  frog              3  
RFRP-2                  SAGATANLPLRS-NH2  bovine            4  
RFRP-1                  MPHSFANLPLRF-NH2  bovine            4 
RFRP-3                          VPNLPQRF-NH2  bovine            4 
GnIH                   SIKPSAYLPLRF-NH2  quail             5     
LPLRFamide                         LPLRF-NH2  chicken           6  
RFRP             ANMEAGTMSHFPSLPQRF-NH2  rat               7 
PrRP20              TPDINPAWYAGRGIRPVGRF-NH2  bovine            8   
PrRP31   SRAHQHSMEIRTPDINPAWYAGRGIRPVGRF-NH2  bovine            8 
C-RFa               SPEIDPFWYVGRGVRPIGRF-NH2  carp              9   
KiSS-14                   DLPNYNWNSFGLRF-NH2  human, rat       10 
P518          TSPGLGNLAEELNGYSRKKGGFSFRF-NH2  human            11 
 
Figure 1. Comparison of RFamide peptides. Residues identical in at least three of the sequences are 
shaded. The number at the end of the line refers to the original publication as follows: 1) Yang et al. 
1985, 2) Satake et al. 2001, 3) Koda et al. 2002, 4) Hinuma et al. 2000, 5) Tsutsui et al. 2000, 6) 
Dockray et al. 1983, 7) Ukena et al. 2002, 8) Hinuma et al. 1998, 9) Fisher et al. 1997, 10) Kotani et al. 
2001, 11)  Jiang et al. 2003. 
 
1.3 Biosynthesis and secretion of neuropeptides 
Neuropeptide precursors are large, often containing sequences of more than one bioactive 
peptide. Preprohormones contain the precursor molecule of a peptide and an N-terminal 
signal sequence that guides the preprohormone through the rough endoplasmic reticulum 
(RER), which is an ATP-dependent process. The signal peptide is removed in the RER and 
reacts with the RER to form a tunnel facilitating the translocation of the peptide chain through 
the RER (Blobel and Dobberstein 1975a, 1975b). Protein folding, disulfide formation, and N-
glycosylation occur in the endoplasmic reticulum (Mains et al. 1987). The biologically inert 
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prohormone is transferred to the cis-face of the Golgi apparatus and from there on to the 
trans-Golgi network, where it is packaged into secretory granules. The neuropeptide 
precursor molecules are located in large, dense core vesicles or secretory granules together 
with the prohormone convertases and other enzymes and usually some other transmitter. 
Sometimes the precursor undergoes post-translational proteolysis before entrance into the 
vesicles, in which case, the products of the same precursors remain in distinct granules. 
Usually a classical transmitter, e.g., acetylcholine or noradrenaline, is coexpressed in the 
neuron or even in the same vesicle as the neuropeptide (Hökfelt et al. 1984, 1986). Before 
excretion, the precursors are cleaved to bioactive peptides, possibly phosphorylated, O-
glycosylated, amidated, acetylated, or sulphated (Mains et al. 1987, Seidah and Chretien 
1997, Steiner 1998). A simplified scheme of peptide biosynthesis and secretion is presented 
in Figure 2. 
S
S
Et
t
t
t
t
Neuron
RER
ER
GolgiSignalsequence
Precursor
Peptides
Precursor without 
signal sequence
 
Figure 2. Peptide biosynthesis and secretion in a neuronal cell. RER=rough endoplasmic reticulum, 
ER= endoplasmic reticulum, t= classical transmitter, E=peptide processing enzyme, S=disulfide 
bridge. 
 
The release of various agents from the nerve terminal and the response they cause are 
dependent on the stimulus of the cell and on the receptors on the postsynaptic membrane. 
The effects of simultaneously excreted agents can be either synergistic or opposing. The 
nerve cells in the same organ may contain different combinations of neuropeptides: e.g., 
substance P is expressed in dorsal root ganglion neurons, and some of these neurons may 
contain dynorphin in addition to SP, while some may contain other neuropeptides. There are 
no publications indicating or denying the coexistence of RFamides with neurotransmitters.  
Once released, the neuropeptides are most often degraded in the extracellular space 
by both specific and non-specific peptidases. The peptidases are numerous, and most of 
them act on several peptides. In a number of neuropeptides, carboxypeptidases remove C-
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terminal basic residues. Aminopeptidases remove the N-terminal amino acids from precursor 
molecules (Lowther and Matthews 2002).  Other peptidase families are vasopeptidases and 
metallopeptidases, which contain a zinc motif. Problems in peptidase activity may lead to 
clinically significant problems such as obesity when the carboxypeptidase E is deficient, 
leading to a severe defect in proinsulin conversion (Naggert et al. 1995). Moreover, 
peptidase inhibitors may also be useful in treating illnesses such as hypertension with 
vasopeptidase (angiotensin-converting enzyme and neutral endopeptidase) inhibitors 
(Campbell 2003). Neuropeptides are ineffective when introduced orally, being rapidly 
degraded in the gastrointestinal tract.  
 The knowledge of RFamide biosynthesis is very limited; it can only be stated that C-
terminal glycine residues required for amidation exist in the precursor (Vilim and Ziff 1995).   
 
1.4 Neuropeptide receptors 
Neuropeptides bind to several types of receptors activating different second messenger 
systems. In addition, the neuropeptides may alter the affinity of a receptor to its specific 
ligand. They bind most commonly to the G protein-coupled receptors, but bind other types of 
receptors, as well. G protein-coupled receptors have seven transmembrane helices and 
activate cyclic adenosine monophosphate (cAMP), phosphatidyl inositol 4,5-bisphosphate 
(PIP), or calcium ions (Ca2+) as second messengers. For example, the      oxytocin-
vasopressin peptide family binds to four receptors, OXY receptor and V1A-, V1B-and V2-
receptors. The OXY receptor is selective for oxytocin over vasopressin, and the rest 
preferentially bind vasopressin. The V2-receptor activates adenylate cyclase and increases 
the amount of cAMP; all the other receptors activate phospholipase C and activate the PIP 
pathway (Hoyle 1999). Additional diversity in neuropeptide effects results from the fact that 
receptors may couple to different kinds of G-proteins (inhibiting or activating), and the effect 
is the calculated sum of all the second messenger systems (Fuxe et al. 1995). Guanylyl 
cyclase is an intracellular enzyme that can be membrane-bound or free in the cytosol (Wedel 
and Garbers 1997). It activates cGMP, a compound similar to cAMP, which contains 
guanosine instead of adenosine. The membrane-bound guanylyl cyclase acts as a receptor 
for atrial natriuretic peptide, and the free guanylyl cyclase is activated by nitric oxide and free 
radicals. Neuropeptides, e.g., FMRFamides (Bowman et al. 1995), interact with nitric oxide, 
and may thus modulate the free guanylyl pathway. Other types of receptors are the one 
transmembrane helix-containing tyrosine-kinase receptors, cytokine receptors, and ion 
channels. Insulin and most growth factors bind to tyrosine kinase-coupled receptors that in 
the cytoplasm initiate a cascade of protein phosphorylations. These receptors are constituted 
of α- and β-chains forming the trans-, intra-, and extracellular domains that contain cysteine-
rich domains (Ullrich et al. 1986). Cytokine-receptor type I receptors bind prolactin and 
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growth hormone and activate Janus Kinase (JAK) or the signal transducer and activator of 
transcription (Stats).  
Neuropeptide receptor types are schematized in Figure 3. 
 
G protein-coupled receptor
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Phosphorylation of proteins
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Figure 3. Scheme representing different types of receptors activated by neuropeptides in different 
organs and cells.  ANP=atrial natriuretic peptide, NO=nitric oxide, JAK/Stats=Janus kinase/signal 
transducer and activator of transcription.  
 
The FMRFamides bind both to G protein-coupled receptors (Higgins et al. 1978) and 
ion channels (Lingueglia et al. 1995). Study of RFamide-peptide receptors in mammals is 
currently somewhat confusing. For example, the same receptor OT7T022 has been 
proposed as a receptor both for deduced RFRP:s (Hinuma et al. 2000) and  for NPFF, called 
the NPFF1 receptor (Bonini et al. 2000). On the other hand, the C-terminal portion of the 
peptide sequence accounts for the binding of the peptide to its receptor (Mazarguil et al. 
2001, Kotani et al. 2001b), and RFRP and NPFF share the last four amino acids at their C-
terminal ends; non-amidated forms are inactive (Kotani et al. 2001b).  
In addition to cardiovascular regulation and hormone-like effects, NPFF possesses 
both anti- and pro-opioid functions, which has complicated the search for a specific receptor. 
Elshourbagy et al. (2000) isolated a 1888kb cDNA encoding a 420 amino acid protein 
resembling orexin A receptor (Sakurai et al. 1998). They tried more than one thousand 
ligands and found that the selective ligands all had RF-termini and bound only to cells 
transfected with both HLWAR77 and a promiscuous G protein α subunit. NPFF and NPAF 
were the most potent ligands, with EC50 values of 13+5 and 22 +6 nmol.  Similarly, (Bonini 
et al. 2000) show that NPFF activates the G protein- coupled receptors NPFF1 and NPFF2. 
These receptors are abundant in human tissues, NPFF1 especially in the spinal cord and 
NPFF2 in the placenta. Mostly, NPFF1 is found in the CNS. Its distribution is quite different in 
the rat, which may be explained by differing effects of the peptide among species. In addition 
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to activation G protein-coupled receptors, NPFF may bind to acid-sensing cation channels 
(Askwith et al. 2000), of which the human heteromeric subtype ASIC2A+3 is mainly 
responsible for these effects (Catarsi et al. 2001). 
All four kisspeptins bind with similar affinity and efficacy to GPR54, a rat receptor 
structurally related to neuropeptide receptors, in particular to galanine receptors (28-40% 
identity) (Kotani et al. 2001a, Muir et al. 2001, Ohtaki et al. 2001). Three publications 
described simultaneously an orphan receptor that binds the kisspeptins that are expressed in 
the placenta and brain. Sequences verified that the AXOR12 (Muir et al. 2001) and 
h/rOT7T175 (Ohtaki et al. 2001) are orthologues of GPR54, the term used in this 
dissertation. The GPR54 seems to be coupled to Gq class proteins, since pertussis toxin has 
no effect on Ca release (Muir et al. 2001,Kotani et al. 2001a). As for most G-protein coupled 
receptors, arachidonic acid release is stimulated and ERK½ and p38 pathways are activated 
by GPR54 (Kotani et al. 2001a). GPR54 is expressed in placenta, pituitary, lymphocytes, 
pancreas, adipose tissue, and brain (amygdala, n. accumbens, hippocampus, cingulate 
gyrus) (Muir et al. 2001). 
Prolactin-releasing peptide was first characterized as a ligand for a G protein-coupled 
receptor UHR1/GPR10-like receptor (Hinuma et al. 1998). This PrRP receptor gene contains 
two exons, one intron, and two polyadenylation signals. Two major and one minor 
transcriptional start-sites exist at 139, 140bp upstream, and –161bp from the translational 
start-site. The promoter region contains several putative binding sites for transcriptional 
factors, but obviously no typical TATA or CAAT box (Ozawa et al. 2002); in their publication, 
they also show that the UHR1/GPR10-like receptor is upregulated in pituitary adenomas and 
downregulated by treatment with bromocriptine, a D2-agonist, which means that the PrRP 
receptor gene is possibly regulated by dopamine.   
 
1.5 Functional properties of neuropeptides 
1.5.1 Energy and fluid homeostasis 
The center for energy balance in the brain is the hypothalamus. It contains several nuclei that 
express neuropeptides taking part in food and water balance. The essential nuclei are the 
arcuate nucleus at the basal hypothalamus just above the median eminence, the 
paraventricular nucleus in the anterior hypothalamus bilaterally to the uppermost third 
ventricle, and the supraoptic nucleus anterior and lateral to the median eminence. The 
ventromedial hypothalamic nucleus is considered to be the satiety center, and the lateral 
hypothalamic nucleus to be the feeding center. The most prominent neuropeptides involved 
in feeding and satiety regulation are NPY, orexins, and galanin. Neuropeptides involved in 
reducing food intake are cholecystokinin and α-MSH. NPY in the arcuate nucleus is inhibited 
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by insulin and leptin, and when functional problems occur in these neuropeptides, the 
experimental animals become obese. (Williams et al. 2001). 
Body fluid balance is also controlled by the hypothalamic paraventricular and 
supraoptic nuclei that project into the neurohypophysis. Neurohypophyseal hormones 
originate from the hypothalamus (Palkovits 1982). As to neuropeptides, the two most 
prominent are vasopressin (VP) and oxytocin (OXY), but also NPFF immunoreactivity exists 
in the neurohypophysis. VP and OXY are synthesized in the magnocellular (VP also in the 
parvocellular) neurons of the paraventricular and the supraoptic nuclei in the hypothalamus, 
but rarely in the same cell. The VP- and OXY-containing magnocellular neurons send axons 
into the neurohypophysis and spinal cord and brainstem, and perform their para- and 
autocrine regulation through the soma and dendrites in the paraventricular and supraoptic 
nuclei. Their precursors contain neurophysin I (OXY) and neurophysin II (VP). Neurophysins 
are cleaved before the formation of the active neuropeptides, but they remain in the same 
secretory granules with OXY and VP (Acher and Chauvet 1995).  
Oxytocin is controlled by and involved in female reproductive functions such as 
coitus, parturition, lactation, puberty and development, circadian rhythm, and plasma 
osmolality (Burbach et al. 1992). Vasopressin is mostly known for its involvement in body 
fluid homeostasis and vascular tone. Because vasopressin mRNA expression is upregulated 
due to hyperosmotic stimuli (Valtin et al. 1965, Majzoub et al. 1983), Brattleboro rats lacking 
the functional vasopressin gene develop diabetes insipidus, an inability to concentrate their 
urine (Schmale and Richter 1984, Schmale et al. 1984).    
NPFF concentration is high in the pituitary and is located in nerve terminal-like 
structures (Kivipelto et al. 1989). Indeed, NPFF is co-regulated with vasopression in the 
neurohypophysis (Majane and Yang 1990, Majane and Yang 1991). NPFF cannot be 
detected in the pituitary of the Brattleboro rat (Majane and Yang 1990), and the amount of 
NPFF immunoreactive material in the heterozyogous animals was diminished, as was the 
amount of vasopressin. Due to a hyperosmotic stimulus, hypophyseal NPFF and vasopressin 
peptide levels are reduced equally (Majane and Yang 1991). Additional evidence exists that 
NPFF affects vasopressin levels: Immunoglobulin G fraction from antiserum against NPFF 
increases vasopressin release in rats (Yokoi et al. 1998). Intracerebroventricular injections of 
NPFF attenuate vasopressin release, and food intake is diminished (Arima et al. 1996, 
Murase et al. 1996, Yokoi et al. 1998, Sunter et al. 2001). 
 The endocrine pancreas contains four types of cells (α-, β-, δ-, and PP-cells) that 
express and secrete glucagon, insulin, somatostatin, and pancreatic polypeptide. Insulin is 
anabolic, increasing the storage of glucose into the liver, and glucagon stimulates hepatic 
glycogenolysis, gluconeogenesis, and ketogenesis. Somatostatin acts in a paracrine manner 
and inhibits the secretion of both insulin and glucagon. The degree of release of insulin is 
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dependent upon the states of activity of various nerve terminals and the phase of the insulin-
secreting β-cell (Ahren 1999). The nerve terminals around the pancreatic islets contain both 
classical neurotransmitters and at least two neuropeptides, vasoactive intestinal peptide and 
pituitary adenylate cyclase-activating peptide (PACAP). (Havel et al. 1997, Filipsson et al. 
1999). NPFF inhibits both prolactin and somatostatin release from the pancreatic islets 
(Fehmann et al. 1990), but because no peptide immunoreactivity has been isolated from the 
pancreas, it may be speculated that its effects are mediated via the blood circulation. 
 
1.5.2 Neuropeptides and prolactin secretion 
Prolactin is a hormone secreted from the anterior pituitary to induce lactation. It was long 
thought that the secretion of prolactin is controlled merely by the inhibitory action of 
dopamine and somatostatin, although researchers were keenly searching for a prolactin-
releasing factor. Endogenous opioids, e.g., β-endorphin (Yang et al. 2000), are reported to 
be involved in prolactin release in stimulated situations such as lactation (Arbogast and 
Voogt 1998) and mating (Yang et al. 2000). Thyrotropin-releasing hormone (at 100 nM, in 
vitro) and vasoactive intestinal peptide are examples of neuropeptides capable of inducing 
prolactin release, although high doses are required. Both NPFF (at 3 and 30 nM, in vitro) and 
PrRP (100 nM-1µM, in vitro) have some prolactin-releasing properties (Aarnisalo et al. 1997, 
Hinuma et al. 1998), but both are more potent in other systems such as cardiovascular 
control (Roth et al. 1987, Samson et al. 2000) and modulation of pain (Roumy and Zajac 
1998).  
 
1.5.3 Cardiovascular control 
Blood pressure and heart rate are centrally controlled by the cardiovascular center in the 
medulla and its connections to the hypothalamus and autonomic nervous system. Various 
neuropeptides are found in these locations, and many of them are indeed involved in 
cardiovascular regulation. NPY is one of the peptides that participates in medullary 
cardiovascular control through medial nucleus of the solitary tract, together with 
catecholamines and excitatory amino acids (Glass et al. 2002). Vasopressin and oxytocin 
inhabit most of the hypothalamic paraventricular and supraoptic nuclei and are obviously 
both involved in cardiovascular regulation directly or through other mediators such as atrial 
natriuretic peptide and nitric oxide (Coote 1995, Cunningham et al. 2002, Petersson 2002).  
 Peptides from the same family may possess completely different properties in 
cardiovascular regulation: endogenous opiates are involved in a controversial manner; γ2-
MSH may be either bradycardic and depressive or tachycardic (at the dose 50-100 nmol/kg) 
and pressor (at the dose 50 nmol/kg), and the other MSHs do not affect blood pressure or 
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heart rate (Klein et al. 1985, de Wildt et al. 1993). The receptor for the actions of γ2-MSH is 
yet to be identified; it is not necessarily a melanocortin receptor but may also be a receptor 
that binds the RFterminus responsible for the cardiovascular effects, such as a NPFF 
receptor or an FMRFamide receptor (Versteeg et al. 1998). ACTH, another derivative of the 
POMC precursor, produces a depressor effect when administered i.v. (at the dose 15-500 
nmol/kg) (Van Bergen et al. 1997, Nakamura et al. 1976), but is clearly advantageous in 
improving blood pressure and pulse amplitude in hemorrhagic shock (at the dose 160 µg/kg) 
(Bertolini et al. 1986).  
  Intravenous NPFF elevates blood pressure, at the dose 15µg/kg (5.5 nmol/kg), in 
rats (Roth et al. 1987). It is found in the central nervous system in areas involved in blood 
pressure regulation, such as the medulla (nucleus of the solitary tract) and hypothalamus 
(Kivipelto et al. 1989), being colocalized with catecholamines (Kivipelto et al. 1992). Allard et 
al. (1995) proposed that the cardiovascular effects of NPFF may also be mediated by 
peripheral mechanisms after revealing NPFF binding sites and NPFF-ir in the heart. Some of 
the cardiovascular effects of intravenous NPFF may, however, be mediated by 
postganglionic neuronal components, since hexamethonium, a ganglionic blocker, partly 
reduces the cardiovascular effects of NPFF. This is in accordance with the results from a 
study performed by Laguzzi et al. (1996), revealing the involvement of the dorsal vagal 
complex in the blood pressure-regulating effects of NPFF. Allard et al. (1995) showed also 
that NPFF could act as a catecholamine modulator. NPFF did not alter catecholamine levels, 
but the effects of NPFF were attenuated in catecholamine-depleted rats: α1- and β1 –
antagonists partially reversed intravenously injected NPFF-induced augmentation in blood 
pressure. On the other hand, α2-antagonists enhanced the pressor and cardioexcitatory 
effects of NPFF. Prazosin, an α1-antagonist, also inhibits the increase in blood pressure 
induced by injections into the nucleus of the solitary tract (Laguzzi et al. 1996). Bilateral 
injections of NPFF into this nucleus provoke a rise in blood pressure and a decrease in heart 
rate, indicating involvement in cardiovascular regulation of the central reflex. Another 
RFamide, the PrRP, has also been shown to increase blood pressure; the doses required 
are, however, large (0.4-4.0 nmol) compared to for example angiotensin (0.1 nmol) (Samson 
et al. 2000). 
Further convincing evidence that NPFF is involved in central cardiovascular 
regulation is that the NPFF neurons in the nucleus of the solitary tract, and those projecting 
into the pontine parabrachial nucleus, are biochemically activated (c-Fos expression is 
induced) in rats after a cardiovascular challenge, this effect being more prominent following 
hypotensive stimulation than after hypertensive stimulation (Jhamandas et al. 1998). The 
development of the putative NPFF agonist and antagonist, PFRFamide and PFR(Tic)amide, 
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respectively (Huang et al. 2000), was thought to be helpful to the investigation of 
cardiovascular effects of NPFF. However, the pharmacological properties of these agents do 
not fully correspond to those of NPFF and need further investigation.  
Like the cardiovascular effect of NPFF (Allard et al. 1995, Huang et al. 2000), PrRP 
also causes hypertension when injected intracerebroventricularly, although heart rate was 
not measured, and the potency of intravenous injection was not tested. PrRP does not seem 
to alter water- or salt appetite as opposed to other peptides known to affect blood pressure 
(Samson et al. 2000). Taking into account that PrRP has a binding site in the heart and is 
also found in plasma (Matsumoto et al. 1999), it is possible that it also has peripheral 
cardiovascular properties. 
 
1.5.4 Neuropeptides, adrenal hormones, and the immune system  
The hypothalamus funnels information from several brain areas (e.g., sensory cortex, limbic 
system, medulla oblongata) and transforms it to hormonal signals. For example, 
corticotropin-releasing hormone, CR, regulates the output of ACTH from adenohypophysis, 
which in turn regulates the adrenocortical secretion of glucocorticoids. The adrenal medulla 
secretes catecholamines, noradrenaline, adrenaline, and dopamine. Enkephalins are part of 
the family of endogenous opioids, and of these methionine-enkephalin (Met-enk), is 
colocalized with adrenaline in the adrenal medulla, where other neuropeptides such as SP 
are also present in the adrenal chromaffin cells. Sympathetic activation increases medullary 
discharge. The adrenal cortex secretes mineralo- and glucocorticoids, and their secretion is 
controlled centrally by the hypothalamus-pituitary system and by changes in plasma ion 
concentration. Adrenal medullary cells may, however, affect adrenocortical secretion in a 
paracrine manner (Nussdorfer 1996). Evidence of NPFF immunoreactivity in the adrenal 
gland is controversial. Labrouche et al. (Labrouche et al. 1998) attested to the presence of 
NPFF immunoreactivity in both adrenal medullary and cortical cells, in areas where NPY is 
found. Our NPFF antibodies fail to bind to the adrenal medulla (Lee et al. 1993, Panula et al. 
1996). It is possible that the antibody Labrouche et al. used crossreacts with either NPY or 
with a neuropeptide from the RFamide family.  
Neuropeptides, e.g., corticotropin-releasing hormone and ACTH, act directly in 
stimulating glucocorticoids that modify immune reactions and indirectly by regulating the 
central nervous system that then generates nerve impulses regulating the immune response. 
Inflammatory processes enhance production of leucocytes, and several neuropeptides are 
strongly involved in inflammation such as SP, which is proinflammatory and somatostatin, 
which is anti-inflammatory. (Berczi et al. 1996). Many neuropeptides are expressed by the 
immune cells themselves. The amounts produced are lower than in neuronoendocrine cells, 
but lymphocytes are far more numerous, and thus the plasma levels of neuropeptides 
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secreted are sufficient (Clarke and Bost 1989).  The neuropeptides may be 
immunostimulatory (αMSH), immunosuppressive (PRL), or immunomodulatory (endorphins, 
VP, OXY, SP) in nature. Neuropeptides such as SP, NPFF (stimulates at a dose 0.1 pM, and 
inhibits at a dose 0.1µM) (Lecron et al. 1992), and somatostin may affect lymphoid cell 
proliferation or may modulate antibody responses (MSH, SP) or production (opiates). Taken 
together, neuropeptides play a regulatory role, despite the low levels of secretion, in immune 
homeostasis, disturbances of which lead to serious autoimmune and allergic diseases 
(Berczi et al. 1996). 
 
 1.5.5 Neuropeptides and ingestion  
Many neuropeptides occur in the epithelium or nervous system of the gastrointestinal tract 
and have various hormone-like effects (Table 3). The neuropeptide-secreting cells in the gut 
are of ectodermal origin, not of neural crest origin, as are those peptide-secreting cells in the 
adrenal medulla and autonomic ganglia. 
 
Table 3. Cells secreting neuropeptides in the gastrointestinal tract. 
 
 LOCATION:  NEUROPEPTIDES: FUNCTION: 
Endocrine cells  Colon SP  Increase motility 
Enterochromaffin cells Whole GI-tract SP, enkephalin Increase motility 
Enteroglucagon cells Ileum Glucagons - 
A cells Stomach Glucagons Stimulate liver glycogenolysis 
D cells Stomach fundus Somatostatin Inhibit secretion of other 
hormones 
G cells  Stomach antrum gastrin17 Stimulate secretion and 
motility 
I cells Duodenum and 
jejunum 
Cholecystokinin Cause gall-bladder 
contraction and secretion of 
pancreatic juice 
Immune cells (blood 
derived or resident) 
Basal lamina of 
GI-tract 
SP - 
K cells Duodenum and 
jejunum 
GIP Inhibit gastric secretion and 
motility 
M cells Duodenum and 
jejunum 
Motilin Affect interdigestive motility 
N cells Ileum Neurotensin Inhibit motility and increases 
ileal blood flow 
S cells Duodenum and 
jejunum 
Secretin Increase secretion of 
bicarbonate 
Enteric neurons Gut walls   SP, NKA, NPY, 
dynorphin, met-
enkephalin 
Enhance motility and 
secretion 
 
The intestines are responsible for digestion of food both chemically (secretions of the 
stomach, duodenum, and exocrine pancreas) and mechanically (peristalsis). Neuropeptides 
are involved in these processes through both central and peripheral regulation. Central 
regulation involves, for example, emotions that cause responses such as diarrhea during 
stress, and constipation in depressive patients. Peripheral regulation consists of actions of 
the enteric nervous and autonomic systems within the bowel walls. The main transmitters are 
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acetylcholine and noradrenaline, but these are often colocalized with neuropeptides. All 
sphincters involved in the gastrointestinal tract are also regulated by neuropeptides.  
NPFF and FMRFamide affect gut contractibility (Raffa and Jacoby 1989, Demichel et 
al. 1993, Decker et al. 1997). The effect of NPFF on the intestines is somewhat 
contradictory, since it seems to block morphine-induced inhibition of bowel movements in the 
ileum (at doses of 10 nmol-1 µmol) (Demichel et al., 1993) but to enhance it in the colon (at 
13 nmol) (Raffa and Jacoby 1989). NPFF affects feeding behavior also through the CNS; 
intracerebroventricular injections of NPFF (5-10µg) reduce food intake (Murase et al. 1996). 
Thus far no evidence links NPFF to the cells of the gastrointestinal tract, and its effects on 
regulation of food ingestion and bowel movements must thus be mediated by the blood. 
NPFF has been detected in human plasma. Measured by radioimmunoassay, the quantity of 
NPFF, 2.9 pg/ml, is insufficient for systemic action, in the light of the K values of NPFF 
receptors being 0.06 nmol (Sundblom et al. 1995).  
 
1.6 Role of neuropeptides in development 
The gene expression of neuropeptides arises at different time-points, and neuropeptides play 
various roles in organ development. Opioid peptides (met-enkephalin, β-endorphin, and 
dynorphin) appear in the brain at embryonal day (E) 11.5 and their receptors later: the µ-
receptor at E12.5, κ-receptor at E14.5, and δ-receptor at postnatal day (P) 0 (Rius et al. 
1991). Somatostatin, neurotensin, and SP immunoreactivities are also apparent during the 
early phases of development (Shiosaka et al. 1981a and b, Hara et al. 1982, Inagaki et al. 
1982, Sakanaka et al. 1982). Some peptides become measurable later during the embryonal 
period, like vasopressin at E16 in the hypothalamus but only at E19 in the pituitary (Buijs et 
al. 1980).  
Neuropeptides may have growth-enhancing or -restricting properties during 
development. Zagon et al. (1999) showed that the met-enkephalin (10 mg/kg) acts through 
the ζ-opioid receptor to inhibit growth in all three embryonal layers (excluding lungs and 
bones) and that this inhibition is reversed by naltrexone.  Met-enkephalin and its precursor, 
proenkephalin A, are expressed in embryonal cells at E20. During early development, 
vasoactive intestinal peptide agonists induce postimplantational growth, and antagonists 
reduce growth (Gressens et al. 1993 and 1994). VIP mRNA is lacking from the mouse 
embryo at this critical period (E9-11), although binding sites and immuoreactivity are present. 
Radioactively labeled VIP injected i.v. into the pregnant female was detected in the mouse 
conceptuses at E10 (Spong et al. 1999). It is thus obvious that VIP of maternal origin is at 
least in part responsible for postimplantational growth during embryogenesis. Insulin-like 
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growth factors are involved in the regulation and development of several organs such as the 
liver (Streck et al. 1992), placenta (Zhou and Bondy 1992), and neurons (Anlar et al. 1999). 
Of all the RFamide peptides only NPFF has undergone study during development of 
rat the CNS from E16 to P28 (Kivipelto et al. 1991). NPFF immunoreactivity appears first at 
E20 in the median eminence as fibers and then disperses on the first postnatal day to the 
nucleus of the solitary tract, to the septal area, nucleus accumbens, stria terminalis, 
retrochiasmatic area, hypothalamus, central gray, inferior colliculus, and parabrachial 
nucleus. In the spinal cord dorsal horn, NPFF immunoreactivity is first apparent on P3. The 
immunoreactive signal strengthens until the age of 2 weeks. From P21 to P28 appear the 
highest number of NPFF-immunoreactive neurons and fibers, and their distribution 
corresponds to that of the adult rat.    
 
1.7 Mechanisms of pain and involvement of neuropeptides 
In human beings, pain is subjective, but can be measured by visual analogy scales 
(Huskisson 1974). The sensation of pain is a consequence of a stimulus strong enough to 
cause tissue damage, and its intensity is proportional to the intensity of the stimulus. 
Responses vary, however, according to psychological states or due to sensitization of the 
sensory afferents (Beecher 1965, Melzack et al. 1982).       
Investigation of sensitivity to noxious stimuli can be studied in animals only 
postnatally. Studies in embryos have concentrated on reflex responses to somatic stimuli, 
reflexes starting in human fetuses at 7.5 weeks of gestation (Bradley and Mistretta 1975) and 
at E15 in the rat (Narayanan et al. 1971), at time-points when spontaneous movements of 
the fetus begin (Narayanan et al. 1971, de Vries et al. 1982). The first area to become 
sensitive is the mouth region and the last the tips of the toes (E19) (Reynolds et al. 1991) 
and the tail region. At birth the reflexes still involve whole-body movement, and the 
cutaneous reflexes are exaggerated in comparison to those of adults (Ekholm 1967, Stelzner 
1971, Issler and Stephens 1983). The somatosensory reflexes begin to change at birth to 
more localized reactions.  
 Pain may be classified as acute, chronic, inflammatory, or neuropathic. Acute pain 
consists of painful stimulation causing the activation of pain fibers by chemical mediators 
such as prostaglandin and bradykinin. If the sensation becomes prolonged without new 
external stimulation, the pain sensation is said to be chronic. Inflammation is represented by 
rubor (redness), tumor (swelling), calor (heat), and dolor (pain). Inflammatory markers are 
many; SP, for instance, has been shown to cause all the typical signs of inflammation, and 
antagonists to SP to completely block the symptoms in humans (Lotz et al. 1988, Murthy et 
al. 1991). Neuropeptides e.g., cholecystokinin (Wiesenfeld-Hallin et al. 2002), galanin 
(Flatters et al. 2003), and NPY (Ossipov et al. 2002), are also involved in neuropathic pain 
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that originates from nerve injury, a pain that has traditionally been very difficult to treat in 
patients, although some have benefited from antidepressant therapy. Interestingly, SP 
depleters (agents that selectively activate C-fibers and cause the release of SP, like 
capsaicin, and thus inhibit the transmission of the painful signal to higher brain areas) have 
proven to be effective when applied topically (Rains and Bryson 1995, Lipman 1996). SP-
inhibitors acting centrally may also prove to be potential pain killers, although there is 
controversy as to their true potency (Monck 2001, Brune 2002). 
 
1.7.1 Pain circuits  
The primary afferent neurons are A and C fibers innervating the muscles, joints, skin, and 
viscera. They sense thermal (>44°C), mechanical, chemical, and polymodal pain. The 
primary sensory afferent fibers enter the central nervous system via the spinal cord dorsal 
horn, where the information is processed by intrinsic dorsal horn neurons. These give rise to 
tracts (spinothalamic, spinoreticular, spinomesencephalic, spinocervical, and postsynaptic 
dorsal column) that convey information to the brain. Each tract usually crosses to the 
opposite side of the spinal cord before reaching its destination and making contact with the 
neurons extending to the higher brain areas. The spinothalamic tract seems to be essential 
for pain (Mayer et al. 1975, Simone et al. 1991). The projection neurons in general are 
involved in controlling the information transferred along the spinal cord by central inhibitory 
pathways (Schaible et al. 1991). The dorsal horn also contains propriospinal neurons and 
local interneurons. Propriospinal neurons convey information along the spinal cord from one 
segment to another, but their role in the sensation of pain is poorly understood. Local 
interneurons transfer information only short distances inside the spinal cord (Figure 4).     
Neuropeptides are found in the spinal cord, and some examples are described here. 
Substance P is found in the primary afferents bringing information to the spinal cord laminae 
I, II, and V (Hökfelt et al. 1975), and SP is released in the spinal cord upon noxious 
stimulation (Duggan et al. 1988). In the rat's ipsilateral paw, SP receptors are activated and 
internalized in the dorsal horn lamina I deep and superficial neurons in response to thermal 
and mechanical stimulation after inflammation (Abbadie et al. 1997). Propriospinal pathways 
also contain substance P (Pickel et al. 1983). NPFF is located in the spinal cord laminae I, II, 
and X at all levels (Kivipelto and Panula 1991). NPFF and NPY are likely to be located in the 
local interneurons, since in the spinal cord rhizotomy does not affect NPFF/NPY content 
(Kivipelto and Panula 1991). Enkephalins also occur in the interneurons (Cuello 1983). No 
evidence exists of descending tracks containing NPFF (Kivipelto and Panula 1991), but 
some NPY-containing neurons in the spinal cord arise from the brainstem in addition to 
arising from the spinal cord itself (Minson et al. 2001). 
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Figure 4. Structure of and pain modulation in the spinal cord. Thin lines represent neurons of the 
spinal cord and primary sensory neurons bringing information from the periphery via C-, Aδ- and Aβ-
fibers. Semi-thin lines represent neurons conveying pain modulatory information in higher brain areas. 
Star and thick line schematizes the tracts conveying information from spinal cord to brain. Origins of 
neurons are marked with black ovals and synapses with small stars. Gray arrows show pain 
modulatory pathways from upper brain regions to the spinal cord. Abbreviations: 1-9=spinal cord 
laminae, Cc=central cervical nucleus, DLPT=dorsolateral pontomecenphalic tegmentum, 
Im=intermediolateral column, Lc=lateral cervical nucleus, Lp=lateral spinal nucleus, 
PAG=periaqueductal gray, PY=pyramidal tract, RVM=rostral ventrolateral medulla.   
 
1.7.2 Pain modulatory pathways 
Wall (1967) reported increased sensitivity to noxious stimuli in decerebrate cats. The 
activation of pain modulatory pathways requires an input from an ascending tract or from the 
rostral brain. A network extends from the cortex to the periaqueductal gray, rostral 
ventromedial medulla, and dorsolateral pontomesencephalic tegmentum via the dorsolateral 
funiculus to the dorsal horn dorsolateral pontomesencephalic tegmentum. Activation of any 
of these areas results in antinociception (Figure 4).  
The pain modulatory pathways can be activated either by electrical or chemical 
stimulation. Pain modulation involves various biogenic substances. Serotonin and 
endogenous opioids such as leu- and met-enkephalin, dynorphin, and β-endorphin are the 
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most common. Serotonin receptors occur in the spinal cord, and their activation produces 
antinociception (Crisp et al. 1991). Other studies indicate, however, that serotonin can either 
facilitate or inhibit spinal nociception (Eide et al. 1990). Rostral ventromedial medulla activity 
induces both serotonin and noradrenaline excretion and produces analgesia blocked by 
serotonin and noradrenaline antagonists. The effects of noradrenaline are mediated by α2-
receptors. Both dynorphin immunoreactivity and mRNA are upregulated in the spinal cord 
dorsal horn following inflammation induced in the rat hind paw (Millan et al. 1988, Ruda et al. 
1988, Weihe et al. 1988).  However, dorsal horn κ opiate-receptor immunoreactivity is 
unaffected by carrageenan-induced inflammation in the hindpaw, and κ opiate receptor 
immunoreactivity content is slightly decreased in the dorsal root ganglion and spinal dorsal 
horn (Ji et al. 1995). In these regions, µ-opioid receptor immunoreactivity is increased in the 
same situation. Similarly, µ-opioid receptor binding increases (Besse et al. 1992), and these 
changes together may well explain the enhanced analgesic effect of exogenous opiates after 
induced inflammation. Visceral sensory information is regulated in the parabrachial nucleus, 
where several neuropeptides occur. For example, neurotensin and somatostatin are 
downregulated in the parabrachial nucleus, whereas SP is first upregulated and then 
depleted completely after vagal stimulation (Saleh et al. 1996). These peptides play different 
regulatory roles in controlling visceral sensory information.  
 
1.7.3 Pain and RFamides 
NPFF was originally extracted as a FMRF-NH2-crossreacting peptide in the bovine brain 
(Yang et al. 1985a); FMRF-NH2 was established as a cardioexcitatory agent also having 
morphine-modulating properties (Greenberg et al. 1983, Tang et al. 1984). Yang et al. 
(1985b) showed that intracerebroventricular NPFF shortens tail-flick latency in naive and in 
morphine-treated rats. To confirm these results, antiserum against NPFF proved to be 
antinociceptive and to enhance morphine- and stress-induced analgesia (Kavaliers and Yang 
1989). Morphine-induced analgesia is reversed by NPFF or its analogs when introduced 
intracerebroventricularly (Oberling et al. 1993) or into the raphe dorsalis (Dupouy and Zajac 
1995). However, this morphine modulation is likely to occur indirectly, since NPFF does not 
bind to opioid receptors (Gouarderes et al. 1998, Dupouy and Zajac 1995). Although when 
injected intrathecally, NPFF potentiates morphine-induced antinociception, an effect reversed 
to some extent by opioid antagonists, evidence existsthat µ- and δ-opioid receptors may play 
a role in NPFF-produced analgesia (Gouarderes et al. 1996). It is also clear that NPFF is 
diminished in the spinal cord after administration of morphine or heroin (Devillers et al. 1995). 
Drawing together all these results, it can be stated that NPFF neurons are involved in a pain 
facilitatory system triggered by opioids (Devillers et al. 1995, Roumy and Zajac 1998). NPFF 
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analogs, produced to be stable against enzymatic degradation, are more potent than is 
NPFF (Gicquel et al. 1992 and 1994).    
 In addition to showing opioid-modulating activity, NPFF immunoreactivity is 
ipsilaterally upregulated in the spinal cord due to carrageenan-induced inflammation 
(Kontinen et al. 1997). Such inflammation reduces the potency of the descending inhibitory 
control of the spinal cord (Pertovaara et al. 1998). NPFF seems, however, to restore the 
effect of this control in a naloxone-independent manner (Pertovaara et al. 1998), providing 
evidence that mechanisms other than only µ-opioid reception are involved in NPFF-mediated 
signaling in the spinal cord. Further evidence that supraspinal controls also affect the NPFF 
system is provided by the work of Lombard et al. (1999). They produced prolonged 
monoarthritis and observed bilateral induction of NPFF binding in the spinal cord on levels 5 
to 6 of the lumbar segments (L5-6), all of which was inhibited by spinal sectioning at the 
thoracic level.   
 Few studies of NPFF in neuropathic pain appeared before 1999. A study by Wei et al. 
(1998) investigated the effect of NPFF in the periaqueductal gray of neuropathic rats: NPFF, 
when introduced into the periaqueductal gray, showed antiallodynic effects in neuropathic 
animals. It was effective only in the monofilament-induced hindlimb withdrawal response and 
produced no significant alterations in the noxious heat- or noxious mechanical-stimuli tests, 
but in the noxious-heat response did reverse the effects of morphine.  
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2. Aims of the study 
 
The purpose of this study was to: 
 
• Clone the NPFF precursor gene in several species 
Yang et al. (1985a) characterized a morphine-modulating peptide from bovine brain by using 
an antiserum generated against molluscan (Macrocallista nimbosa) FMRFamide. Two 
peptides were identifiable by affinity-column chromatography and reverse-phase HPLC: the 
NPFF and SLAAPQRF. NPFF’s role in pain and other functions was thereafter extensively 
studied for review; see Panula et al. 1996. To further improve our understanding of the 
peptide and its mechanisms, it was of interest to clone the gene. 
 
• Characterize NPFF mRNA distribution in the rat  
Previous studies have shown that the NPFF peptide distribution is largely confined to the 
central nervous system. High expression levels exist in the spinal cord and in the pituitary. 
However, NPFF also has some peripheral effects (Panula et al. 1996). It was therefore of 
interest to characterize gene expression both in the central nervous system and the 
periphery. While conducting this work, another RFamide peptide, the prolactin-releasing 
peptide, PrRP, was characterized (Hinuma et al. 1998). Since PrRP belongs to the same 
family as NPFF and has some similar functions (Aarnisalo et al. 1997, Hinuma et al. 1998) it 
was of interest to include it for comparison and for understanding of the peptide family as a 
whole. 
 
• Study RFamide gene expression during ontogeny 
NPFF immunoreactivity appears in the rat embryo at embryonic day 20. The 
immunoreactivity thereafter spreads, reaching an adult-like appearance at the postnatal age 
of 4 weeks (Kivipelto et al. 1991). It was of interest to reveal the mRNA expression during 
embryogenesis in order to clarify the role of the peptides during ontogeny. 
 
• Characterize essential functional properties of NPFF and PrRP 
Because NPFF immunoreactivity in the spinal cord is induced in inflammatory pain (Kontinen 
et al. 1997), it was of interest to see whether NPFF gene expression levels would be affected 
in the spinal cord or in other pain-mediating areas in the CNS. The pain-modulating role of 
NPFF has been well studied (Panula et al. 1996), but no such data existed for PrRP, 
although it shares with NPFF the C-terminal RF-terminus responsible for receptor binding. It 
was of interest to reveal the role of PrRP in pain. 
      Hypophyseal NPFF originates from the hypothalamus (Majane et al. 1993) and is most 
probably coregulated with vasopressin (Majane and Yang 1990). PrRP is found in the 
hypothalamus in fibers that synapse with oxytocin-containing neuronal soma (Maruyama et 
al. 1999). These facts led to our investigation of NPFF- and PrRP mRNA levels in the brain 
during salt loading.  
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3. Materials and methods  
 
3.1 Ethics 
All animal experiments were carried out according to the local rules and guidelines approved 
by the Åbo Akademi University Animal Care and Use Committee, the Office of the Regional 
Governments of Western, and Southern Finland, and guidelines of the European Convention 
(Strasbourg, 1986).  
 
3.2 Animals  
All experiments were done on the laboratory rat, a widely used and well characterized model. 
Male Sprague Dawley rats were used in all experiments unless otherwise stated. Rats were 
housed in groups of 3 to 4, and were allowed standard laboratory pellets (Special Diet 
Services, Witham, Essex, UK) and fresh water ad libitum. The rats were kept under a 12-
hour dark/light cycle.  
Embryos: Sprague Dawley rats were mated overnight, with the following day counted 
as the first embryonic day, E1. Embryos of gestational ages E14, 15, 16, 17, 18, 19, 20, 21, 
and rat puppies (both male and female) postnatal day 0 (P0) were anesthetized with CO2 and 
decapitated, and these embryos were quickly dissected. Sex was determined from the 
prepared slides under a microscope. Placentas were collected from 1 to 2 embryos of each 
age. Placentas and embryos were used both for immunohistochemistry and for in situ 
hybridization.  
For real-time quantitative RT-PCR, embryos were kept in sterile 0.9% NaCl and 
dissected as quickly as possible to obtain the following organs separately: placenta, gut, 
kidney, adrenals, stomach, spleen, pancreas, lung, heart, thymus, spinal cord (caudal neural 
tube), and hindbrain (rhombencephalon), midbrain (mesencephalon), and forebrain 
(prosencephalon). Each type of organ from 3 to 8 individuals (all from one litter) were pooled 
in one tube and frozen quickly in liquid nitrogen. Samples were stored at –70°C until further 
analysis. 
 
3.3 Experimental models 
3.3.1 Hyperosmolar stimulus (III) 
This model was designed according to earlier salt loading experiments (Sherman et al. 
1986a and b, Meister et al. 1990, Majane and Yang 1991). This study used 3 groups of 6 
male rats. The first group was served as a control; these animals were given tap water to 
drink. The second group received 2% NaCl to drink for a week. The third group received 2% 
NaCl for a week and then tap water for another week to see any possible rebound effect. 
Pellets were given ad libitum to all animals. 
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3.3.2 Methods for assessing pain (I) 
Rats were anesthetized with halothane. Inflammatory pain was mimicked by an injection of 
carrageenan (Sigma) into the left hind paw, and the effect was monitored (inflammatory 
signs) and by weighing of the paw of the decapitated rat. 
In our work, we used the spinal nerve ligation (Kim and Chung 1992), in which the L5 
and L6 spinal nerves are ligated with silk thread on the left side under pentobarbitol 
anesthesia. Only animals with unilateral allodynia to mechanical stimulation with 
monofilaments (withdrawal threshold <4.2g) were taken into the studies. For more detailed 
descriptions see I. 
  
3.3.3 Injections 
For the insertion of the intrathecal cannula, rats were anesthetized with a subcutaneous 
injection of midazolam 5.0 mg/kg (Dormicum®; Roche, Basel, Switzerland) and 1.0 ml/kg of 
Hypnorm® (fentanyl 0.2 mg/ml and fluanisone 10 mg/ml; Janssen Pharmaceutica, Beerse, 
Belgium). Intrathecal injection: A thin polyethene cannula (PE-10; Meadox Surgimed A/S, 
Stenløse, Denmark) was inserted through the cisterna magna into the lumbar subarachnoid 
space, 8 cm from the insertion, and fixed with a suture to the paravertebral muscles (Yaksh 
and Rudy 1976).  
For intracerebral injections, the rats were implanted with a chronic guide cannula made 
of stainless steel (26 gauge) in a standard stereotaxic frame under general anesthesia 
(pentobarbitone 50 mg/kg i.p.), and behavioral testing was done as described in detail earlier 
(Wei et al. 2001). The injection sites were in the periaqueductal gray (PAG) (AP -1.36 mm, ML 
0.7 mm, DV 6.0 mm), nucleus tractus solitarius (NTS) (AP -3.3 to -4.3 mm, ML 1.3 mm, DV 7.8 
to 8.2 mm), and caudal ventrolateral medulla (CVLM) (AP -4.3 mm, ML 1.8 mm, DV 10.6 mm). 
After the experiments, brains were postfixed and sectioned to verify the injection sites. As the 
injection volume was 0.5 µl, it dispersed to an area of 0.5 mm in radius and was thus easily 
seen with bare eye, with no staining required. 
 
3.4 Cloning 
This dissertation project was originally aimed at cloning the NPFF gene. Rat and bovine 
brainstem mRNA extracts were used for rt-PCR. cDNA was synthesized from mRNA by 
reverse transcriptase, and a variety of oligonucleotide probes were tried for amplifying the 
desired sequences. The probes were designed with the knowledge that rat, bovine, and 
human peptides are identical (Majane et al. 1988).  After successful cloning of the NPFF 
gene (Vilim and Ziff 1995), this study was undertaken as a collaborative effort (I). 
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3.5 Immunohistochemistry (I) 
Tissues for immunohistochemistry were obtained from rats anesthetized with 
Mebunat (Orion, Helsinki, Finland) and perfused transcardially with physiological saline and a 
proper fixative. Our peptides were linked to keyhole limpet hemocyanin for immunizing the 
rabbits, and the rat tissues were fixed with 4% paraformaldehyde and then immersed in 20% 
sucrose overnight before freezing. Samples were kept at –20°C until sectioning on gelatine-
coated (prepared in our laboratory) slides or Super Frost Plus slides (Menzel Gläser, 
Braunschweig, Germany). Slides were air dried for 1 to 2 hours at room temperature before 
storage at –20°C. 
Immunohistochemistry was used to localize peptide distribution in the tissues 
examined. Antisera used in these studies were polyclonal rabbit antisera obtained by 
immunizing rabbits with intradermal injections of the peptide in question (for a detailed 
description see I) and then bleeding the rabbits every 10 days to obtain antiserum. The 
antiserum specificities were then checked by crossreactivity tests with other known peptides 
before being used in definitive tissue analysis.  
 
Table 4. List of antisera used. 
 
ANTISERUM MADE AGAINST DILUTION REFERENCE CROSS-
REACTIVITY 
NPFF  
#1E 
FLFQPQRF-NH2 1:500 Kivipelto et 
al.1989 
- 
NPSF  
#61C 
SLAAPQRF-NH2 1:1000 I 1 µM NPFF 
PrRP20 
#81B 
TPDINPAWYAGRGIRPVGRF-
NH2 
1:2000 our unpublished 
observations  
- 
PrRP8  
#86C 
GIRPVGRF-NH2 1:2000 our unpublished 
observations 
1 µM PrRP20 
  
3.6 In situ hybridization (I-IV) 
For in situ hybridization, tissues were frozen fresh in isopentane on dry ice and stored at -
70°C until sectioned at -20°C. Sections were cut at -20°C to 20 µm thickness and thaw- 
mounted on poly-L-lysine slides (Menzel Gläser, Braunschweig, Germany).  
In these works, mainly sulphur (35S) radiolabeled probes were used. The protocols 
are described in detail in I: full-length cDNA, and in IV: oligonucleotide. In principal, RNA was 
first fixed in the tissues under ultraviolet light, and the tissues were then adjusted to the 
hybridization conditions by pipetting of prehybridization solution (similar to the hybridization 
solution, but with no probe) onto the slides which then remained for 1 to 2 hours at the 
optimal hybridization temperature. The temperature depended on the length of probe and of 
nucleotide content (50°C for all except PrRP oligonucleotide, for which 45°C was used). The 
hybridization solution contained agents that enhanced the hybridization signal and blocked 
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unspecific binding of the probes. The next day, excess probes were washed away under 
stringent conditions, and the samples were dried.  
 
Table 5. Probes used for ISH. An equal molar mixture of a and b served for NPFF and UHR1/GPR10-
like receptor in situ hybridizations. 
 
PROBE AND 
REFERENCE 
SEQUENCE BINDS TO NUCLEOTIDES 
CORRESPONDING TO 
AMINO ACIDS 
NPFF cDNA (I) Full-length NPFF cDNA in pGEM-3Z - 
NPFF  
oligonucleotide a 
(II-IV) 
5’-CAA GCA TTT CTA CCA AAC CTC TGG 
GGC TGA AAC AAG AAG GCT GGG TTC 
CTT CTA-3’ 
226-261 
FQPQRFGRNAW 
NPFF  
oligonucleotide b 
(II-IV) 
5’-GGG AAG TGA TTT TGC ATG CAG 
ACA TAT CAC AGC AGA TGA TGT TAC 
TTC TT-3’ 
337-387 
KK*HHLL*YVCMQMNHF 
PrRP  
oligonucleotide 
(II-IV) 
5’-TTG ATA CAG GGG TTC TTGG TCT 
CCA TGG AGT GCT GGT GGG CTC 
GGCC CTG GA-3’ 
64-102 
SRAHQHSMETRTP 
UHR1/GPR10 
oligonucleotide a 
(II-IV) 
5’-TGC AGC TCT GGG AAC CGT CGC 
AGA CAC ATT GCT CTC TGA AGC CTC 
TGC ACT-3’ 
105-155 
SAEASESNVSATVPRAA 
UHR1/GPR10 
oligonucleotide b 
(II-IV) 
5’-AGC GCC AGC ACT GCA GAT AGA 
GCC CAG ATG CCC AGC ACA GCG TAG 
GCG CTG-3’ 
545-595 
SAYAVLGIWALSAVLA 
VP CC  
(II) 
Vasopressin exon C 241bp fragment in 
pGEM-3 
- 
 
3.7 Measurements and statistics 
3.7.1 Measurements 
In all experiments the results were obtained for at least 3 separate animals (6 in the salt- 
loading experiment). In analysis of embryos, each of the 3 embryos was from a different 
litter. Embryos collected for quantitative PCR analysis were all from the same mother; each 
type of organ from 3 to 8  embryos were pooled for analysis. 
Samples were analyzed blindly when any two treatments (salt loading/tap water, 
carrageenan/vehicle) were compared. For salt loading, each of the three groups was 
compared with one another. For carrageenan, only one concentration of drug was used.  
 
3.7.2 Quantification of gene expression (I, II) 
Signal intensities from film autoradiographs were analyzed with a computer-assisted MCID 
program (Imaging Research Inc., St. Catharines, Ontario, Canada).  
Individual cells and their areas were recorded under a darkfield microscope and a 
connected computer-assisted analysis program (analySIS) to reveal whether the treatment 
affected the number or size of the cells expressing NPFF or vasopressin or the PrRP gene. 
The areas for the whole nuclei were also measured. Grain densities were counted under a 
darkfield microscope by aid of a phase analysis program (analySIS) to see whether the gene 
expression level in an individual cell underwent any influence.  
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3.7.3 Statistics  
Values obtained with the MCID program or analySIS were then loaded into the Prism 
biostatistics computer program, and paired t-tests (I), or oneway Anova followed by 
Bonferroni’s multiple comparison tests (I-II) were performed. P<0.05 was considered 
significant. 
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4. Summary of results 
 
4.1 Structure of the NPFF gene (I) 
Three bioactive PQRF-peptides had been identified (Majane and Yang 1987). The gene was 
cloned from human, rat, bovine, and mouse tissues, and all three peptides previously found 
were located in the gene. All three genes have a similar organization with two introns and 
three exons. NPFF (FLFQRQRF-NH2) is located at the junction of exons 2 and 3; intron 2 is 
located in the middle of the NPFF peptide sequence. NPAF (AGEGLSSPFWSLAAPQRF-
NH2) is located entirely in exon 3 of the rat. NPSF (SLAAPQRF-NH2) is located in the exon 
3 of the rat (Figure 5). 
 
NPFF
PrRP
KiSS
RFRP (C7orf9)
EXON 1
EXON 1
EXON 1
EXON 1
5 UT
3 UT
5 UT
5 UT
5 UT
3 UT
3 UT
3 UT
EXON 2
EXON 2
EXON 2
EXON 2
EXON 3
EXON 3
EXON 3
EXON 3
EXON 4
S
NPFF NPAF
PrRP31 PrRP20
RFRP (C7orf9)
KiSS
 
Figure 5. Comparison of known RFamide gene structures. NPFF, PrRP, and RFRP consist of three 
exons and two interweaving introns (lines). The KiSS precursor differs from the three others by having 
four exons and three introns. The light gray areas show untranslated regions, and peptide coding 
sequences are black or striped (NPAF). S=signal peptide. As is evident, the NPFF sequence is 
interrupted by the second intron in the precursor. Similarly, the PrRP31 is disrupted by an intron, but 
exactly at the site where PrRP20 is cleaved from PrRP31. These schemes are modified from I; 
(Yamada et al. 2001, West et al. 1998, Schulz et al. 2002),  respectively. C7orf9 is the gene locus 
encoding RFRPs in the Schulz article. 
 
The mRNAs are 600 to 800 bp in length and encode peptide precursors of 113 to 115 amino 
acids in length. The precursors of all species share a 40% overall identity. The genes encode 
C-terminal consensus sequences, and cleavage from these sites results in the bioactive 
peptides isolated by Majane and Yang (1987). However, the N-terminal processing site is 
located three amino acids N-terminally to the active amino-terminus of NPFF. Either some 
non-identified cleavage mechanisms exist, or the bioactive peptides undergo some 
degradation.  
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4.2 NPFF and PrRP gene expression in the rat tissues  
 4.2.1 Central nervous system (I-III) 
According to our comparative immunohistochemical studies (unpublished observations), 
PrRP and NPFF/NPSF immunoreactive fibers in many areas of the CNS overlapped. PrRP 
immunoreactivity was characterized by an N-terminal antibody (#86C) and a C-terminal 
antibody (#81B), of which the C-terminal antibody gave more intensive reactions (Figures 8B 
vs C and E vs. F). NPFF/NPSF-like immunoreactivity was strong in the posterior pituitary 
(Figure 6A), whereas PrRP immunoreactivity was virtually absent from the posterior pituitary 
(Figures 6B and C), not demonstrating a role for PrRP in prolactin release. PrRP was 
ineffective when administered intrathecally (data not shown), and PrRP immunoreactivity 
was also absent from the spinal cord (Figure 7B), whereas NPFF/NPSF immnoreactivity was 
strong in the spinal cord dorsal horn laminae I and II (Figure 7A). The trigeminal nucleus 
displayed NPFF/NPSF immunoreactivity, but no PrRP fibers or cells were present (Figures 
7C-D). PrRP immunoreactivity (data not shown) as well as PrRP mRNA expression are more 
prominent in the caudal nucleus of the solitary tract, but some PrRP immunoreactive fibers 
were also visible in the medial nucleus of the solitary tract (Figures 8A-C) where NPFF/NPSF 
immunoreactivity was strong (Figure 6A). Both peptides occurred in the parabrachial nucleus 
(Figures 8D-F), in the periaqueductal gray (Figures 9A-B), and in the thalamic paraventricular 
nucleus (Figures 9C-D). When the antiserum was preabsorbed with 100 µM of the peptide, 
all reactions were abolished (data not shown). 
 
 
Figure 6. A: NPFF/SLAAPQRF and B: PrRP (#86) C: PrRP (#81) -immunoreactivity in the pituitary. 
Sections are consecutive. Pictures were taken with a fluorescent microscope with a 10x objective. 
Scale bar 500µm. PL=posterior lobe, IML=intermediate lobe, AL=anterior lobe. 
 
 
Figure 7. A: and C: NPFF/SLAAPQRF, B: and D: PrRP (#81) –immunoreactivities in consecutive 
sections of the spinal cord dorsal horn (A&B) and in the trigeminal nucleus (C&D). Pictures were taken 
with a fluorescent microscope with a 25x objective. Scale bar 500µm. I, II, and III in B mark the 
corresponding laminae of the spinal cord dorsal horn. The coronal level of the section of the trigeminal 
nucleus is visible in the lower right corner of D and the area photographed is visualized by a white 
rectangle on a schematized sagittal section in D. 
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Figure 8. A: NPFF/SLAAPQRF, B: PrRP (#81) and C: PrRP (#86) immunoreactivities in consecutive 
sections in the medial NTS. D: NPFF/SLAAPQRF, E: PrRP (#81) and F: PrRP (#86) 
immunoreactivities in consecutive sections of the parabrachial nucleus. Pictures were taken with a 
fluorescent microscope with a 25x objective. Scale bar 500µm. The coronal level of the section of the 
medial NTS is visible in the lower right corner of C, and the area photographed is visualized by a white 
rectangle on a schematized sagittal section in C. Corresponding indications for the parabrachial 
nucleus are seen in F. LPBV=lateral parabrachial nucleus, PBW=waist of the parabrachial nucleus, 
and MPB=medial parabrachial nucleus. 
 
 
 
Figure 9. A: NPFF/SLAAPQRF and B: PrRP (#81) immunoreactivities in consecutive sections in the 
PAG. C: NPFF/SLAAPQRFand D: PrRP (#81) immunoreactivities in the thalamic paraventricular 
nucleus under the third ventricle in adjacent sections. Pictures were taken with a fluorescent 
microscope with a 25x objective. Scale bar 500µm. 
 
In our studies (I-IV), NPFF, PrRP, and UHR1/GPR10-like receptor mRNAs were all 
expressed in the medulla and hypothalamus, but in different nuclei: NPFF mRNA occurred in 
the rostral solitary nucleus, while PrRP mRNA was expressed in the commissural part of the 
nucleus of the solitary tract. The UHR1/GPR10-like receptor mRNA was present in the area 
postrema in the medulla. NPFF mRNA was present in the hypothalamus in the 
paraventricular and supraoptic nuclei. PrRP mRNA was identified in an area between the 
dorsomedial and ventromedial hypothalamic nuclei, which is the same area where NPFF 
immunoreactivity previously appeared (Panula et al. 1996). Hypothalamic receptor mRNA 
was found in the walls of the third ventricle and additionally in the reticular thalamic nucleus. 
Only NPFF mRNA was found in the spinal cord dorsal horn laminae I and II. These data are 
summarized in a schematic drawing as Figure 10. The PrRP and UHR1/GPR10-like receptor 
mRNA expressions have been published by other groups (Fujii et al. 1999), and our results 
are in accordance with those data.    
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Figure 10. Schematic drawing showing NPFF (black), UHR1/GPR10-like receptor (dots) and PrRP 
(gray) mRNA expression in the adult rat central nervous system. Stripes=PrRP and UHR1/GPR10-like 
receptor simultaneously. A=Bregma -1.80—2.12 mm, B=Bregma –13.68, C= Bregma –13.80. The 
drawings are modified, and the coordinates are from Paxinos and Watson (1996). 
 
4.2.2. Peripheral tissues (IV) 
We observed strong expression of NPFF mRNA only in the spleen, which supports the view 
of a NPFF role in lymphocyte proliferation (Lecron et al. 1992). A weak, evenly distributed 
signal was detectable in the lung. PrRP mRNA was evident in the pancreas, adrenal 
medulla, testis, and epididymis. The PrRP receptor UHR1/GPR10-like receptor mRNA was 
found in all the same tissues as PrRP mRNA, except for the pancreas. Among the tissues 
examined no sign of mRNA expression of these peptides was detectable in the gut or the 
heart. The results are summarized in Figure 11.  
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Epididymis and testis 
Adenohypophysis
 
Figure 11. NPFF (black) and PrRP (gray) mRNA in peripheral tissues of the rat. Black and white 
stripes show areas where PrRP and UHR1/GPR10 mRNA are seen simultaneously. 
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4.3 Embryonal mRNA distribution of NPFF and PrRP (III) 
 4.3.1 Central nervous system 
In this study, only NPFF mRNA was present in the youngest embryos, and appeared in the 
spinal cord and in the medulla. NPFF expression remained in these structures until birth and 
still remained in the adult rat. At E15, UHR1/GPR10-like receptor mRNA became evident in 
the pallidum, from whence it extended to the hippocampus-differentiating field and to the 
medullary reticular formation gradually at E16 and E17. NPFF mRNA appeared in the 
medullary reticular formation at the same time as UHR1/GPR10-like receptor mRNA. At this 
time, NPFF mRNA became visible also in the hypothalamus differentiating field. PrRP mRNA 
appeared in the CNS only at E18 in the nucleus of the solitary tract. PrRP and UHR1/GPR10 
mRNA appeared in the pontine isthmus from E20 to E21. UHR1/GPR10-like receptor mRNA 
disappeared also from the hippocampus-differentiating field and pallidum before birth. The 
embryonal pituitary showed a weak but steady in situ hybridization signal with all three genes 
from E18 to P0. NPFF mRNA expression in the medullary reticular formation was transient. 
See Figure 12. The placenta displayed a weak but steady signal for all three genes: PrRP 
and NPFF mRNA were detectable in the labyrinthine part and UHR1/GPR10-like receptor 
mRNA in the junctional zone of the placenta.  
 
4.3.2 Peripheral tissues  
NPFF mRNA expression during development followed the same distribution as in the adult 
rat: NPFF mRNA occurred as a weak signal in the lung  (E18-P0) and as a stronger signal in 
the spleen at P0. PrRP mRNA was displayed in the testis, kidney, and in the liver. 
UHR1/GPR10-like receptor mRNA was expressed in the adrenal gland, as in the adult rat, 
but was not found in the same organs as the PrRP mRNA. All three genes were expressed in 
the placenta throughout the ages studied. NPFF and PrRP mRNA were present in the 
labyrinthine part of the placenta, and UHR1/GPR10-like receptor in the junctional zone of the 
placenta. See Figure 12 for summary. 
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Figure 12. Schematic drawings summarizing NPFF, PrRP, and UHR1/GPR10-like receptor mRNA 
expression during embryogenesis in the rat. Black=NPFF mRNA, dots=UHR1/GPR10-like receptor 
mRNA, gray=PrRP mRNA, and black and white stripes show the areas where all three mRNAs are 
seen simultaneously. A: E14, B: E16, C: E18, D: E20 and E: P0. Anatomical areas are labeled when 
the expression is seen in them for the first time. Note that at E14 only NPFF mRNA is expressed. At 
E16, some areas express UHR1/GPR10-like receptor mRNA, and PrRP is first seen at E18 in the 
liver, testis, kidney, and NTS. The isthmus expresses PrRP and the receptor only E20-E21, and NPFF 
mRNA can be seen in the spleen after parturition. E=embryonal day, P=postnatal day, 
Hippoc=hippocampus, HDF=hypothalamus-differentiating field. 
 
4.4. Effect of hyperosmolar stimulus on NPFF and PrRP gene expression (II) 
We gave the rats hyperosmotic saline to drink for a week and after this observed that NPFF 
gene expression was almost completely abolished from the hypothalamic magnocellular 
neurons in the paraventricular and supraoptic nuclei. mRNA levels returned to initial values 
after a week’s rehydration period (all rats had access to tap water ad libitum). NPFF mRNA 
in the medullary nuclei expressing the peptide gene remained, however, at control levels 
throughout the dehydration experiment. 
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 PrRP is expressed in an area between the dorso- and ventromedial hypothalamic 
nuclei in the hypothalamus, and neither the mRNA levels of this nucleus nor medullary nuclei 
expressing PrRP mRNA were changed. When mRNA expression levels of the 
UHR1/GPR10-like receptor were studied, no apparent changes were observable in either the 
hypothalamic reticular nucleus or in the area postrema in the medulla. 
 
4.5. NPFF and PrRP in pain models  
 4.5.1 Neuropathic pain   
NPFF mRNA expression was not altered in the spinal cord after ligation of the spinal nerve 
ligation (I). 
 In our work, analgesic properties of systemically administered PrRP were studied in 
both normal and neuropathic rats. Intrathecal PrRP had no effect on their spinal reflexes 
(data not shown). PrRP20 injected into the nucleus of the solitary tract of normal rats 
produced a significant (Figure 13A) dose-dependent (Figure 13B) mechanical antinociception 
not reversible by naloxone (Figure 13C). PrRP20  produced only a weak hyperalgesic effect 
when introduced into the caudal ventrolateral medulla (Figure 13A). When PrRP20 was 
injected into the nucleus of the solitary tract or central gray, it also had an antiallodynic effect 
(Figures 13D-E). (Unpublished observations).  
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Figure 13. PrRP and pain modulation. A: The analgesic effect of PrRP is site-specific: only PrRP into 
the nucleus of the solitary tract (NTS) produced significant analgesia, and PrRP into the PAG had a 
small hyperalgesic effect. B: The analgesic effect of PrRP in the NTS was dose-dependent. C: 
Naloxone did not reverse the pain-modulating effect of PrRP. D: In neuropathic rats, PrRP produced a 
significant tactile allodynia at doses of 0.2 nmol and 0.5 nmol in the NTS, and E, in the periaqueductal 
gray (PAG).   
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4.5.2 Inflammatory pain  (I) 
According to our investigations, NPFF mRNA was upregulated in the spinal cord dorsal horn 
due to carrageenan-induced inflammation in the hind paw. Both the relative gray scale 
values on the autoradiographic films and the absolute number of cells expressing NPFF 
mRNA were increased, both by approximately 150%. These results are in accordance with 
changes observed in peptide levels under similar experimental conditions (Kontinen et al. 
1997). PrRP or UHR1/GPR10-like receptor mRNAs are not expressed in the spinal cord (our 
unpublished observations), and have thus not been studied in a similar setting.
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5. Discussion 
 
5.1 RFamide peptide gene structure, expression and regulation (I) 
Perry and co-workers have identified the NPFF precursor gene from human testis (Perry et 
al. 1997). In our work, we cloned the NPFF precursor mRNA from human, rat, mouse, and 
bovine brain (I). The precursor is conserved among bovine, rat, murine species and amonog 
human beings (Vilim and Ziff 1995, I) with overall sequence identities among all these 
species of 40%. In human and bovine genes, with a sequence identity of 71%, another 
potential peptide-ending RPamide was processed, but this was absent from the rat or murine 
genes. In the precursor gene, an Arg-Arg cleavage motif and Arg-Gly amidation site should 
produce peptides three aminoacids longer in the rat and mouse (I). According to a recent 
study (Bonnard et al. 2001), evidence exists of a difference in peptide maturation among 
animals. In the rat spinal cord, this NPA-NPFF seems to be responsible for the physiological 
activity of NPFF (Roumy et al. 2000), and adequate enzymes for aminoacid cleavage occur 
in the spinal cord. In the mouse, however, the postulated mature peptide of sequence SPA-
NPFF is not detectable in the spinal cord; either the cleavage does not occur in the spinal 
cord but elsewhere, or the SPA-NPFF is degraded very rapidly. 
Perry et al. (1997) cloned the human NPFF-related peptide by using a human 
genome database and PCR. They showed that the structures of the peptides deduced differ 
from the earlier biochemically isolated peptides. The longer peptide has two substitutions, 
and the shorter peptide is extended by three amino acids at its N-terminal end (human 
NPSF).  Human NPSF requires proteolytic cleavage or other mechanisms to remove the 
three amino acids in order to gain a physiologically active peptide, the biochemically-isolated 
peptides experience a form of degradation. Alternative transcripts cannot be produced from 
the human NPFF gene, since it contains two introns without open reading frames or splice 
sites other than the ones used to produce the transcript identified from the isolated cDNA 
clone. They had, in accordance with our results, no alternatively spliced mRNAs detectable, 
despite several cloning efforts.  
 
5.2 RFamide peptide genes in development (III)
 
While this study on RFamide mRNA expression during rat embryogenesis was in progress, 
three reports on PrRP expression during development appeared (Yano et al. 2001, Yasui et 
al. 2001, Reis et al. 2002). Yano et al. show that PrRP mRNA and peptide immunoreactivity 
are first seen in the CNS at E18 in the NTS and at E20 in the reticular nucleus of the medulla 
and that the signal appears only at P13 in the hypothalamus. Their results are in accordance 
with ours; we detected no PrRP in the hypothalamus. The latest time point assessed in our 
study was, however, P0. In addition to their work we reported mRNA expression in the 
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peripheral tissues and placenta; the placental expression was similar to that found by Reis et 
al. (2002) and Yasui et al. (2001).   
NPFF mRNA expression differed from the appearance of NPFF immunoreactivity 
during embryogenesis (Kivipelto et al. 1991), and mRNA expression was evident earlier in all 
areas of the brain than was the peptide immunoreactivity. For example, in the spinal cord, 
mRNA was visible at E14, which was the earliest time-point examined, and the peptide 
appeared only at P3. This discrepancy could be due to a methodological problem; the 
antiserum used in (Kivipelto et al. 1991) is, however, still  considered one of the most specific 
NPFF antisera available. Moreover, considering the fact that the NPFF binding sites appear 
postnatally between P14 and P28 (Desprat and Zajac 1994), it is reasonable that the 
peptide, as well, matures only postnatally. Another possibility for the differing timing of mRNA 
and peptide detectivity is a yet-to-be characterized mechanism of posttranslational 
processing in which this delay is equally long. 
 
5.3 Functional significance of RFamide peptides 
5.3.1 Body fluid homeostasis and RFamide peptides (II) 
Considering the effects of PrRP in food and water intake, food intake and body weight gain 
were reduced, but water intake was unaffected after intracerebroventricular injection of PrRP 
(2-4 nmol) (Lawrence et al. 2000, and 2002). Since the catabolism induced by PrRP 
resembled that of leptin, they investigated the interactions of PrRP and leptin.  PrRP-ir 
neurons in the CNS contained leptin receptors, and both had additive effects in reducing food 
intake and weight-gain. Both peptides reduced body temperature, a phenomenon increased 
when these peptides were introduced simultaneously. Sunter et al. (2001) suggest that 
NPFF-effected reduction in food intake is a consequence of increased water intake. In our 
study (II) on the effect of the hyperosmotic stimulus, PrRP mRNA levels were not significantly 
altered in the hypothalamus, whereas NPFF has previously and also in our study shown 
regulation by dehydration (Majane and Yang 1990, and 1991, Boersma et al. 1993).  
PrRP is more likely to be involved in other regulatory mechanisms in the 
hypothalamus. A pathway of fibers reaches from the NTS to the hypothalamic neurons which 
synapse with the paraventricular neurons, suggesting that PrRP may play a role in control of 
hypothalamic hormone release (Maruyama et al. 1999). Indeed, it was thereafter shown, 
during the preparation of our report, that PrRP receptor-expressing neurons co-express CRH 
in the bed nucleus of stria terminalis (BST) (Lin et al. 2002). PrRP is therefore likely to act on 
BST neurons, which then modulate the PVN parvocellular neurons regulating CRH release, 
and in this way participate in the stress response of the hypothalamo-pituitary-axis.   
In contrast to our expectations, we found, however, that the hypothalamic NPFF 
mRNA levels after salt loading were not augmented but drastically decreased. This decrease 
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is a possible result of differentially expressed transcription factors (Nystedt et al. 2002), 
which then may inhibit NPFF gene expression in a fashion similar to that of other sites where 
NPFF is not produced or may be due to a completely different mechanism. In hypothalamic 
stress, the morphology of the surroundings is changed, and the astrocytic processes are 
withdrawn from between the neurons (Hatton 1997), causing the neurons to be in closer 
contact with each other. These results, taken together, mean that NPFF and PrRP act 
through differing mechanisms for food digestion and water absorption. 
 
5.3.2 RFamides and peripheral functions (IV) 
PrRP binding sites have been characterized in various peripheral organs (Satoh et al. 2000). 
Indeed, we found PrRP and the UHR1/GPR10-like receptor mRNA expression to occur 
widely in the periphery, including the anterior pituitary, adrenal medulla, the testis, and 
epididymis, but in the pancreas only PrRP. We did not study adipose tissue or muscle, and in 
the gut investigated only the duodenum. In contrast to Satoh’s work, we found no PrRP or its 
receptor mRNA in the heart. PrRP was originally seen as a prolactin-releasing agent, but has 
thereafter been shown to be involved in other mechanisms (Samson et al. 2000, Lawrence et 
al. 2000), and our results together with other data (Roland et al. 1999) further demonstrate 
the importance of PrRP as a regulator of autonomic homeostasis. 
 Of all peripheral tissues we examined, NPFF mRNA was expressed only in the 
spleen, a fact which supports NPFF’s role in the proliferation of lymphocytes (Lecron et al. 
1992, Minault et al. 1995). Despite the NPFF effect on gut motility (Raffa and Jacoby 1989), 
no NPFF immunoreactivity has been found in the gut autonomic nervous system or in the 
endocrine cells (Lee et al. 1993), and accordingly, we detected no NPFF mRNA in the 
duodenum.  
 
5.3.3 PrRP, NPFF, and pain 
The pain-modulatory effects of NPFF have been obvious since the finding of the peptide 
(Yang et al. 1985a). Since then, NPFF has been linked to morphine modulation (Malin 1990a 
and b, 1991a and b), inflammatory pain (Kontinen et al. 1997, Lombard et al. 1999), and to 
neuropathic pain (Courteix et al. 1999, Altier et al. 2000). Because NPFF peptide levels were 
upregulated in the spinal cord due to inflammation in the rat hind paw (Kontinen et al. 1997), 
we investigated possible changes in NPFF mRNA expression in the same area of the spinal 
cord after a similar inflammation in the hind paw. In accordance with the results of Kontinen 
et al. (1997), we found that NPFF mRNA levels were upregulated (I). Since no NPFF 
peptide-ir or NPFF mRNA can be found in the spinal dorsal ganglia (Panula et al. 1996), 
NPFF is apparently present in the local interneurons in the spinal cord laminae I and II and 
possibly interacts with substance P, glutamate, or dynorphin–containing interneurons (see 
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Figure 4). However, no morphological verification was performed, as the study aimed at 
cloning the NPFF gene and showing the histological distribution of NPFF mRNA. 
As NPFF has morphine-modulating properties, are its effects mediated through opioid 
µ-, δ-, and κ-receptors (Magnuson et al. 1990,Gouarderes et al. 1996, Desprat and Zajac 
1997)? Answers to this question are quite controversial, and any effects detected are small 
(Gouarderes et al. 1998) or indirect (Goodman et al. 1998, Ballet et al. 2002), and mostly 
mediated by δ-receptors (Chen et al. 2000), but NPFF evidently downregulates µ-opioid 
binding sites (Rothman et al. 1993, Goodman et al. 1996). It is therefore more likely that 
NPFF effects are mediated through other types of receptors. 
Evidence indicates, however, that the antinociceptive effects of NPFF may be 
mediated through stimulation of nitric oxide synthase (Malin et al. 1996, Zajac et al. 2000), 
since intraventricular injection of 10µg NPFF produces a quasimorphine syndrome that is 
alleviated by 7.5 to 15 mg/kg of subcutaneous L-NAME (Malin et al. 1996).  
PrRP and NPFF share a C-terminal RFamide structure, and since this structure 
accounts for most of the binding of the protein to its receptor, we assessed the involvement 
of PrRP in pain. Lin et al. (2002) also propose that PrRP may play a role in nociception, as 
UHR1/GPR10-like receptor is co-expressed with enkephalin in the parabrachial nucleus. The 
pain-modulating effects of PrRP were clear in our study, but obviously the mechanisms differ 
from those of NPFF, as can be seen from Table 6.  
 
Table 6. Pain modulation by NPFF and PrRP in neuropathic (Ne) and normal animals (ctrl). 
 
SITE OF 
ADMINISTRATION 
PEPTIDE/DOSE EFFECT RECEPTORS 
INVOLVED 
REFERENCES 
Ventricle NPFF/dose -> 
 
 
 
 
PrRP 
Antiallodynic 
(15 nmol) in ne,  
hyperesthetic 
(0.8 nmol) and 
analgesic in ctrl 
Not studied 
Partly µ-opioid 
receptor 
 
Altier et al. 2000 
Oberling et al. 1993 
Periaqueductal 
gray 
NPFF/0.05 nmol 
 
PrRP/0.5 nmol 
Antiallodynic in 
ne,  
Analgesic in 
ne,  
no effect in ctrl 
Partly µ-opioid 
receptor 
Not known 
Wei et al. 1998 
 
our unpublished 
observations 
Nucleus of the 
solitary  tract 
NPFF 
PrRP/0.5 nmol 
Not studied 
Analgesic in 
both 
 
Not µ-opioid 
receptor 
 
our unpublished 
observations 
Caudal 
ventrolateral 
medulla 
NPFF 
PrRP/0.5 nmol 
Not known 
Hyperalgesic in 
ctrl 
 
Not known 
 
our unpublished 
observations 
Spinal cord NPFF/5 nmol 
 
PrRP/0.5-10 
nmol 
Analgesic in 
both 
No effect 
Partly µ-opioid 
receptor 
Xu et al. 1999 
 
our unpublished 
observations 
 
The doses used for PrRP were pharmacological, and the amount of endogenous 
neuropeptide released in a single synaptic cleft may also be large although the neuropeptide 
concentration in a given amount of tissue is often low. As the injection volume was 0.5 µl, 
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and dispersed to a larger area than a single nucleus, the effects of PrRP may be mediated 
through any adjacent area to the site of administration. 
 
5.4 Expression of the UHR1/GPR10 -like receptor 
The UHR1/GPR10-like receptor mRNA is expressed in the reticular thalamic nucleus 
and zona incerta, in the periventricular area of the 3rd ventricle, and in the area postrema in 
the medulla (Roland et al. 1999, Ibata et al. 2000, II-IV), and in the paraventricular nucleus, 
amygdala, and bed nucleus of the stria terminalis (Lin et al. 2002). The peripheral tissues 
expressing UHR1/GPR10-like receptor are anterior pituitary, adrenal medulla, and male 
reproductive organs (IV, V). Lin et al. used different primers for obtaining the cDNA probes 
than did Roland et al., and we have used synthetic oligonucleotides. Because in situ 
hybridization is a technically demanding method, it is possible that areas of lower expression 
are not always visible. 
As we have shown that PrRP (10 nmol-1 µmol) and NPFF (1-10 nmol in vitro) were 
both involved in at least prolactin release and pain modulation and that they had a common 
RFamide structure, it is not surprising that recently Engström et al. (2003) discovered the 
binding of PrRP to NPFF2 receptors.  
  
5.5 Methodological considerations 
Several methods exist for in situ hybridization: fluorescence, digoxigenin, or 
radiolabeling with 125I, 33P, or 35S. Probes can be synthetic or full-length or fragments of cDNA 
grown in plasmids. The choice was easy, since the radioactive method using 35S was already 
established in our laboratory, and the gene expression of NPFF was so low that it was 
difficult to detect with digoxigenin-labeled full-length cDNA (data not shown). The advantage 
of radiolabeling the probes rather than immunolabeling is the longivity of the data, but also in 
addition to slides, the possibility to analyze samples from autoradiographs. The choice 
between radioligands was determined by safety: the radiation diameter of 35S is shorter than 
that of 125I or 33P, but the signal strong enough. The advantage of using synthetic 
oligonucleotides rather than cDNA is the simplicity of the procedure, its good reproducibility, 
and avoidance of many toxic agents.   
We used fluorescent immunohistochemistry. The avidin-biotin-complex is another 
broadly used detection system, and is based on the high affinity of avidin to biotin. The 
advantage of fluorescent labeling is its speed and simplicity. Avidin-biotin-complex staining is 
performed on free-floating tissue sections, which permits the use of more diluted antisera 
(e.g., 1:10 000 vs. 1:2 000). This method's multiple steps and harmful chemicals are its 
greatest disadvantages. On the other hand, the samples remain forever, unlike the 
fluorescent dye that slowly fades away in weeks.  
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  Our antibodies were tested for possible cross-reactivities before their use in 
experimental settings (for details, see Kivipelto et al. 1989). In the early 1980’s, FMRFamide 
stainings were confusing, since the antibodies crossreacted with NPY which shares a similar 
C-terminal structure with FMRFamides (Hökfelt et al. 1983). The antibodies used these 
studies crossreacted neither (I) with NPY nor with related peptides.  
 Inflammatory pain can be mimicked by introducing either formalin (Dubuisson and 
Dennis 1977), carrageenan (Kayser and Guilbaud 1987,Hylden et al. 1991), or complete 
Freund´s adjuvant (mineral oil containing killed Mycobacterium butyricum at 10mg/ml) into 
the skin (Iadarola et al. 1988) or a joint (Schaible et al. 1987) of an animal. The inflammatory 
response lasts from 1 to 8 hours. The response is limited to the injection site, with no signs of 
systemic disease (Iadarola et al. 1988) or other side-effects. Carrageenan is widely used in 
our laboratory and was therefore chosen for these studies.  
 Neuropathic pain is caused by injury to the nerve followed by plastic changes in 
neuronal circuitry and pain perception. Experimental neuropathic pain can be produced by 
ligating the sciatic (Bennett and Xie 1988, Seltzer et al. 1990) or spinal nerves (Kim and 
Chung 1992) of experimental animals. Assessment involves testing with mechanical and 
thermal stimulation for the effect of the neuropathic surgery. The advantage of spinal nerve 
ligation is the standard surgical procedure and the fact that injured nerves are completely 
separated from intact nerves.   
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6. Summary and conclusions 
 
• The NPFF precursor gene was cloned (I) and found to be identical with a sequence 
identified earlier (Perry et al. 1997). The precursor mRNA contained the sequences for all 
three biochemically active peptides, NPFF, NPAF, and NPSF, and it was preserved among 
the species tested: rat, mouse, bovine, and human. 
 
• The distribution of NPFF mRNA was characterized throughout the rat tissues. This 
peptide was prominently expressed in the central nervous system: hypothalamic 
paraventricular and supraoptic nuclei, medullary nucleus of the solitary tract and trigeminal 
complex, and the spinal cord dorsal horn (I). Of the peripheral tissues, NPFF mRNA was 
found only in the spleen (IV). The embryonal distribution corresponded largely to the adult 
NPFF mRNA-expressing areas but differed from the NPFF immunoreactivity found in the 
embryo (III). Thus, there is a considerable delay in translating the gene into a mature protein, 
and this may be due to a post-translational regulatory mechanism yet to be characterized.  
 
• NPFF immunoreactivity has been found in the hypothalamus in an area (Kivipelto et al. 
1989) with no NPFF mRNA present (I), which led to the question of other RFamide peptides. 
Hinuma et al. (1998) cloned PrRP, and PrRP mRNA was indeed found exactly in the 
hypothalamic nucleus exactly where NPFF immunoreactivity but not mRNA was evident. 
Among other researchers, we characterized PrRP mRNA distribution in the brain and 
periphery (IV). PrRP was expressed in the male reproductive organs both in embryo and in 
adult rats, and in the kidney and liver (III, IV). The PrRP and UHR1/GPR10-like receptor 
mRNA expression during embryogenesis largely corresponded to the adult distribution (III), 
except for the hypothalamic nuclei, which began to express PrRP only postnatally.  
 
• NPFF mRNA expression was enhanced in response to the carrageenan inflammation 
in the spinal cord ipsilaterally to the inflammation (I). PrRP was also involved in nociceptive 
pathways, not via the spinal cord but through the medulla. PrRP (0.5 nmol) was analgesic 
when injected into the nucleus of the solitary tract (dorsal medulla) in normal and in 
neuropathic rats and analgesic also when injected into the periaqueductal gray of 
neuropathic but not of normal rats. The PrRP-mediated analgesia was not mediated via µ-
opioid receptors. 
 
• Contrary to our expectations, during chronic hyperosmolar stress the hypothalamic 
NPFF mRNA was not up- but downregulated (II), neither medullary NPFF, PrRP, nor 
UHR1/GPR10-like receptor mRNA was affected by the treatment. No significant changes 
were evident in hypothalamic PrRP or UHR1/GPR10-like receptor mRNA levels. This result 
suggests a possibly novel transcriptional regulatory mechanism.   
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